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Breast cancer can develop when genes that control the cell cycle and genomic 
stability are aberrantly expressed or non-functional.  CHFR encodes an E3 ubiquitin 
ligase that reportedly delays mitosis in response to microtubule-targeting drugs (i.e. 
nocodazole and taxanes).  Loss of CHFR mRNA expression has been reported in many 
cancers, including breast cancer, but the relevance of this to tumorigenesis remains 
unknown.   
To test if CHFR was relevant for mammary tumorigenesis, we analyzed the 
effects of altered expression in breast cancers.  Nearly 40% of cultured and primary 
breast cancers had low or no CHFR, which was associated with large tumor size in 
patient samples.  Decreased CHFR expression by RNAi in immortalized human 
mammary epithelial cell (IHMEC) lines resulted in taxane sensitivity and the acquisition 
of tumorigenic phenotypes including faster growth rates, higher mitotic indices, enhanced 
invasiveness and motility, epithelial-to-mesenchymal transitions, increased aneuploidy, 
and colony formation in soft agar.  Conversely, over-expressing CHFR in breast cancer 
cells caused slower growth and decreased invasiveness and motility.   
xii 
To determine if CHFR was critical for genomic stability, cells transfected with 
CHFR siRNA were analyzed for chromosome segregation defects.  Transient CHFR loss 
led to increased aneuploidy, misaligned metaphase chromosomes, anaphase bridges, 
multi-polar condensed spindles, multi-nucleated cells, and mislocalization of the mitotic 
checkpoint proteins MAD2 and BUBR1.  CHFR was found to interact with three proteins 
required for mitotic spindle formation and chromosome segregation, including MAD2 
and Aurora A where CHFR loss led to elevated Aurora A oncoprotein levels, but no 
change in MAD2 expression.  Alpha-tubulin was identified as a novel target for CHFR-
mediated ubiquitination and degradation after treatment with nocodazole.  Decreased 
CHFR increased acetylated α-tubulin, a mitotic spindle protein implicated in cellular 
response to taxane treatment.   
These findings indicate that CHFR has tumor suppressive qualities and may be a 
biomarker for chemotherapeutic response to taxanes.  CHFR has a previously 
unrecognized role as a regulator of genomic stability via its functional impact on BUBR1, 
MAD2, Aurora A, and α-tubulin.  CHFR may be one of the few proteins that can control 
the cell cycle, chemotherapeutic response, and genomic stability - processes that go awry 









 Breast cancer is a relatively common malignancy and is the most frequently 
diagnosed cancer in women in the United States.  According to the American Cancer 
Society, one in eight women will be diagnosed in their lifetime.  It is estimated to account 
for 26% of all new cancer cases and will likely be the second leading cause of cancer-
related death in American women in the year 2007 [1].  
The American Society of Clinical Oncology (ASCO) currently recommends 
testing for four breast cancer biomarkers, combined with traditional characterization of 
tumor grade and stage, in order to predict prognosis, recurrence, and course of treatment.  
ASCO recommends that every primary invasive breast cancer should be analyzed for 
estrogen and progesterone receptor (ER and PR, respectively) expression status in order 
to identify cancers that will be responsive to endocrine therapies such as anti-estrogens 
and aromatase inhibitors.  Though the prognosis of ER and PR positive tumors used to be 
poor because they were non-responsive to traditional chemotherapy such as paclitaxel, 
they now have a favorable prognosis due to these targeted therapies.  Testing for HER2 
expression and/or amplification is also recommended in order to determine if patient 
treatment should include trastuzumab.  Her2 is a member of the epidermal growth factor 
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receptor (EGFR) family and its expression has been associated with aggressive tumors 
and poor prognosis.  ASCO also recommends that newly diagnosed, early stage non-
metastatic breast cancers should be tested for the expression of urokinase plasminogen 
activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) as low levels of these two 
proteins indicate a low risk of cancer recurrence.  High expression of these biomarkers 
has also been associated with increased invasion, metastasis, and angiogenesis.  Finally, 
ASCO suggests that newly diagnosed, early stage ER-positive breast cancers should be 
subjected to gene expression profiling, particularly with the RT-PCR based Oncotype DX 
assay, which measures the expression of 21 genes.  This assay can be used to predict the 
risk of recurrence in patients treated with tamoxifen.  Other gene expression profiling 
methods, including microarrays, have been considered for diagnosis, treatment 
indications, and the prediction of prognosis, but they have not been adequately tested in 
order to be recommended by ASCO [2].  Other biomarkers for breast cancer prognosis 
and disease progression also have been considered, such as ploidy status, p53 expression, 
and cyclin E expression, but none have demonstrated sufficient evidence to support their 
use in clinical practice [2].        
There are several ways to treat breast cancer, including surgery, radiation therapy, 
endocrine therapy such as anti-estrogens, and chemotherapy.  The most common drugs 
recommended to be used in combination in early breast cancer are cyclophosphamide, 
methotrexate, fluorouracil, doxorubicin (adriamycin), epirubicin, and the microtubule-
targeting drugs, paclitaxel (Taxol), and docetaxel (Taxotere) [1].  However, the tumor 
response to the chosen therapy is highly dependent on the molecular and genetic changes 
that have occurred in order for the cancer to arise.  For instance, anti-estrogen therapy 
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will be ineffective if the cancer does not express the estrogen receptor (ER).  Therefore, 
researchers and clinicians must identify the molecular and genetic characteristics of the 
tumor in order to determine the best course of treatment.  Paclitaxel and docetaxel belong 
to the class of drugs called taxanes, which destabilize the microtubules of actively 
dividing cells, such as cancer cells, resulting in their death by apoptosis.  Other 
microtubule-targeting drugs including nocodazole and colcemid, which over-stabilize 
microtubules, can induce an apoptotic response similar to the taxanes but they are not 
used for chemotherapy.  One potential biomarker for chemotherapeutic response to 
taxanes is the expression of CHFR, though very little is known about this protein, its role 
in tumorigenesis, and its cellular functions.   
CHFR Protein Structure and Homologs 
Checkpoint with FHA and Ring Finger (CHFR) was initially identified in a screen 
to find novel mitotic checkpoint proteins containing a forkhead-associated (FHA) domain 
[3].  In addition to the N-terminal FHA domain, CHFR also has a central RING finger 
domain and a C-terminal cysteine-rich region (Figure 1.1) [3].    The functional relevance 
of the FHA domain in CHFR remains largely unknown, except that its deletion creates a 
dominant-negative form of the protein, suggesting that it is critical to its normal cellular 
function [3, 4].  The zinc-binding RING finger domain has proven essential for the early 
prophase checkpoint function of CHFR.  It confers CHFR’s E3 ubiquitin ligase activity, 
which creates ubiquitin chains on target proteins either via the amino acid residue lysine-
48, thereby targeting proteins to the proteasome for degradation, or via lysine-63 linkages 
that may alter target proteins’ function [5, 6].  The RING finger domain is also necessary 
for CHFR auto-ubiquitination [7].  Recently, the cysteine-rich region was identified as 
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the interacting region between CHFR and one of its target proteins, Aurora A [8].  
Recently, a putative C2H2 zinc-finger motif, which was renamed a PAR-Binding Zinc-
finger (PBZ) motif, was identified in the C-terminal cysteine-rich region of CHFR.  This 
region was found to be poly(ADP-ribosyl)ated by PARP1.  Although mutating the PBZ 
domain did not inhibit CHFR’s ubiquitinating activity, it did impair the dominant-
negative function of the FHA-domain deletion mutant.  There was also inconclusive 
evidence that the PBZ motif may be required for CHFR’s early mitotic checkpoint 
function [9].  Of interest, the targeting of proteins to portions of the mitotic apparatus is 
dependent on the recognition of poly(ADP-ribose) (PAR) by PAR-binding motifs.   
According to the domain architecture and organization, there are evolutionarily 
conserved protein orthologs of CHFR even in yeast, both Saccharomyces cerevisae and 
Schizosaccharomyces pombe (Figure 1.1) [3, 10].  These minimally described orthologs, 
Defective in Mitotic Arrest 1 and 2 (Dma1 and Dma2), were important for regulating the 
mitotic spindle checkpoint, mitotic spindle position, and cytokinesis through the 
septation-initiation network [10-12].  As will be described later, two studies indicated that 
human and mouse CHFR may have similar functions as the yeast orthologs.   
Interestingly, a human paralog of CHFR was described recently.  Ring finger 
protein 8 (RNF8), shares the FHA and RING domains architecture of CHFR, though it 
appears to have diverged a bit in terms of cellular function (Figure 1.1).  Initially, RNF8 
was described as a mitotic protein important for spindle formation, cytokinesis, and 
mitotic exit, much like the yeast orthologs [13].  However, unlike CHFR, it also was 
characterized recently as an important DNA damage response protein to double-strand 










Figure 1.1: The protein structures of CHFR and CHFR homologs 
CHFR and CHFR homologs have variable length N-termini followed by phospho-protein 
binding FHA domain and a RING domain, which is required for E3 ubiquitin ligase 
activity.  The human CHFR protein also has a C-terminal cysteine-rich region though its 
paralog, Ring Finger protein 8 (RNF8), does not have this region.  CHFR is 
evolutionarily conserved and yeast orthologs, Dma1 and Dma2, have been characterized 









RNF8’s FHA domain, in order to mediate double-strand break associated ubiquitinations 
and facilitate the accumulation of 53BP1 and BRCA1 at DNA double-strand breaks [14, 
15].  Both groups noted that RNF8 ubiquitinates histones H2A and H2AX and that loss of 
RNF8 expression by RNAi abrogated double-strand break retention of the ubiquitin-
binding protein RAP80 and increased cellular sensitivity to ionizing radiation [14, 15].   
There is a growing amount of evidence that CHFR, unlike RNF8, does not 
mediate a classical cellular response to DNA damage based on results from commonly 
used assays to assess DNA damage response.  While the role of CHFR in the cellular 
response to ionizing radiation has been inconclusive [16, 17], it does not seem to have a 
role in the DNA damage response induced by cisplatin (CDDP), UV radiation, or the 
topoisomerase inhibitors etoposide (VP16) and Topotecan  [7, 18, 19].                                                        
Since its initial publication, studies on CHFR have primarily focused on its 
expression in cancer cells and potential role in oncogenesis, but some progress also has 
been made in identifying its biochemical function and target proteins.  This chapter will 
address the discoveries that have been published to date for CHFR, including its mitotic 
checkpoint functions, reported protein targets for its ubiquitin ligase activity, and 
evidence supporting its role as a tumor suppressor protein and biomarker for 
chemotherapeutic response to taxanes.                  
 
CHFR Checkpoint Functions 
The Microtubule-Stress Prophase Checkpoint 
As mentioned above, CHFR does not seem to participate in the DNA damage 
checkpoint or DNA repair pathways.  On the contrary, CHFR regulates an early mitotic 
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checkpoint, during prophase, in response to the disruption of normal microtubule 
formation or stabilization as assessed after treatment with microtubule poisons such as 
nocodazole, colcemid, and taxanes [3].  During mitotic stress, CHFR temporarily delays 
the cell cycle by about three hours, during which chromosome condensation and nuclear 
envelope breakdown is inhibited, and Cyclin B1/Cdc2 is restricted to the cytoplasm 
where it is inactive [3, 17, 18].  CHFR also regulates the coordination of chromosome 
condensation and centrosome separation during prophase [3].  Together, these results 
identified CHFR as the first key member of a novel early mitotic checkpoint in prophase, 
referred to here as the CHFR-mediated prophase checkpoint (Figure 1.2).   
The ability of CHFR to delay chromosome condensation has been confirmed both 
by visually identifying a lack of condensed chromosomes and by the absence of 
phosphorylation of histone H3 on residues Ser10 and Ser28 when CHFR is over-
expressed in several cell lines [3, 17, 18, 20].  In addition, the CHFR-mediated prophase 
checkpoint is typically monitored by calculating the mitotic index of cells treated with 
microtubule poisons; CHFR expressing cells will have fewer mitotic cells, as evidenced 
by condensed chromosomes and no nuclear envelope, compared to non-expressing cells 
[3, 18, 20, 21].     
 Elegant studies performed by Kang et al. in Xenopus laevis egg extracts have 
begun to elucidate how CHFR regulates entry into mitosis.  As previously mentioned, 
CHFR delayed the onset of mitosis by retaining inactive Cyclin B1/Cdc2 in the 
cytoplasm in human cells.  In X. laevis extracts the addition of full-length CHFR, but not 
RING finger mutants, resulted in prolonged inhibitory phosphorylation of Cdc2 on 









Figure 1.2: Four cell cycle checkpoints regulate the entry and completion of mitosis. 
The CHFR-mediated prophase checkpoint occurs after the DNA damage checkpoint, 
during prophase, in response to altered microtubule dynamics.  The mitotic spindle 
checkpoint regulates the metaphase-anaphase transition later in mitosis.  The “abnormal 
spindle orientation” checkpoint associated with the EB1 protein has only been identified 




 proteins Wee1 and Cdc25C at the G2 to M transition.  However, the steady-state level of 
expression for these proteins, and the Cdc25C regulatory protein Chk1, remained 
unchanged in the presence of CHFR, indicating that they were not probable 
ubiquitination targets.  Therefore, it is likely that the prolonged inhibitory 
phosphorylation of Cdc2 at Tyr15 is due to the over-activation of Wee1 kinase, which 
phosphorylates Cdc2 at Tyr15, and the inhibition of Cdc25C phosphatase that is normally 
responsible for activating Cyclin B1/Cdc2 by removing the inhibitory phosphorylation on 
Tyr15 of Cdc2 (Figure 1.3).   
One of the proteins that can regulate both Cdc25C and Wee1 via phosphorylation 
is polo-like kinase 1 (PLK1).  Kang et al. determined that CHFR could, in fact, 
ubiquitinate PLK1 in X. laevis extracts [6].  In support of this model, the E3 ubiquitin 
ligase activity of CHFR via its RING finger domain is required for proper checkpoint 
function, suggesting that CHFR must ubiquitinate a target protein for the cell cycle delay 
to occur.  However, though the pathway described above is a likely explanation for the 
series of events that occurs downstream of CHFR in response to mitotic stress, these 
results have not been easily replicated in mammalian cells.  The ability of CHFR to 
ubiquitinate and/or regulate PLK1 has not been consistently reproduced, raising questions 
as to the legitimacy of this pathway in mammalian cells, as discussed further below.   
Another potential pathway for the CHFR-regulated mitotic stress checkpoint 
during prophase is through the p38 stress-activated kinases in which CHFR acts upstream 
of p38 through an as-of-yet unknown mechanism [23].  There is also evidence that 
Sirtuin 2 (SIRT2), a tubulin and histone deacetylase, may also participate in the same 






Figure 1.3: CHFR may coordinate mitotic entry by controlling Cyclin B1 
translocation to the nucleus via negatively regulating PLK1 and Aurora A activity. 
 
CHFR negatively regulates Aurora A, and possibly PLK1, by ubiquitinating these 
proteins and targeting them for degradation by the proteasome.  When CHFR inactivates 
PLK1 and Aurora A, the Wee1 and Myt1 kinases inhibit the Cyclin B1/Cdc2 complex by 
inhibitory phosphorylation on residue Tyr15 and prevent its translocation to the nucleus 
in order to initiate mitosis.  In addition, the Cdc25c phosphatase is never activated by 







expression results in a decreased mitotic index and inhibited chromosome condensation 
in response to nocodazole or paclitaxel treatment.  The NAD-dependent tubulin 
deacetylase activity of SIRT2 was required for this response [24].  Finally, another 
potential player in the mitotic stress-induced prophase checkpoint is Sensitivity to 
Nitrogen Mustard 1 (SNM1).  Akhter et al. found that mouse embryonic fibroblasts from 
Snm1 knockout mice behaved like human cells that had lost CHFR expression.  Snm1 
null cells arrested during the spindle checkpoint with condensed chromosomes and 
separated (and duplicated) centrosomes following nocodazole exposure whereas wild-
type cells from littermates arrested with decondensed chromosomes and unseparated 
centrosomes [25].  Furthermore, Snm1 wild-type cells delayed mitotic entry by about four 
hours and maintained cyclin A expression longer, indicating an arrest in prophase, when 
compared to null fibroblasts [25].  Much like CHFR null human cells, Snm1-/- mouse 
embryonic fibroblasts were less likely to survive nocodazole treatment when compared to 
wild-type cells [25].  Of interest because the CHFR homolog RNF8 can regulate 53BP1, 
Akhter el al. also found that Snm1 could interact with 53bp1 and the APC/cyclosome 
complex [13, 25].   Together these observations suggest that a currently unrecognized 
pathway of protein interactions involving CHFR is critical for normal progression 
through the recently described prophase checkpoint. 
The Mitotic Spindle Assembly Checkpoint 
In addition to participating in an early mitotic checkpoint during prophase, one 
report indicated that CHFR might be required for later events in mitosis, such as 
chromosome segregation, to maintain genomic stability.  Embryonic fibroblasts from 
Chfr knockout mice not only showed a prolonged time in prophase, but also an extended 
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amount of time in anaphase.  The Chfr null mouse embryonic fibroblasts, which became 
aneuploid in culture, also displayed lagging chromosomes during anaphase, failed nuclear 
segregation, and multi-nucleated cells indicating failed cytokinesis [8]. In support of 
these findings, recently published bioinformatics evidence indicated that CHFR may 
contain a KEN box motif, indicating that CHFR may be targeted for proteasome-
mediated degradation by the anaphase-promoting APC/C complex, which is a critical 
component of the mitotic spindle assembly checkpoint and the regulatory complex that 
controls mitotic exit [26]. Therefore, CHFR may have multiple mitotic checkpoint 
functions and, contrary to initial thought, does not function only in response to mitotic 
stress due to microtubule-targeting drugs.     
 
CHFR Interacting Proteins 
Polo-like Kinase 1 (PLK1) 
 As mentioned previously, there is evidence that CHFR can ubiquitinate PLK1 in 
Xenopus extracts, but tests to assess the ability of CHFR to regulate PLK1 activity or 
protein levels in mammalian cells have been inconclusive.  Findings in support of CHFR 
controlling PLK1 include results indicating that over-expressed CHFR mutants, which 
mimic unphosphorylated CHFR, can decrease PLK1 expression and kinase activity in 
HeLa cells [16].  Of interest, mouse embryonic fibroblasts from Chfr knockout mice were 
found to over-express PLK1 compared to cells from wild-type and heterozygous 
littermates, suggesting that CHFR can ubiquitinate PLK1 to target it for degradation [8]. 
 To the contrary, there are other reports that have not been able to find a 
correlation between CHFR expression and PLK1 expression or activity.  For example, 
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Matsusaka and Pines were unable to find an association between PLK1 expression and 
induction of the CHFR-mediated prophase checkpoint due to colcemid treatment [23].  In 
addition, other studies have not been able to find a relationship between CHFR 
expression and the amount of PLK1 protein, either as a trend among breast cell lines or 
following CHFR over-expression in HCT116 cells [17, 21].  It is apparent that more work 
is required to determine if PLK1 is a target for CHFR-mediated ubiquitination and 
regulation.  Perhaps the interaction is specific for a particular species, tissue, or treatment.  
Aurora A kinase 
Another protein that regulates the activity and translocation of cyclin B1 to the 
nucleus to initiate mitosis is Aurora A kinase [27].  Therefore, Aurora A has also been 
speculated to be a target for ubiquitination by CHFR.  Summers et al. analyzed Aurora A 
expression and activation in HCT116 cells over-expressing CHFR and found that even 
though there was no change in Aurora A expression or localization to the centrosomes, 
they did discover that the nocodazole-induced CHFR-mediated mitotic delay was 
associated with inactive Aurora A that was unphosphorylated at residue Thr288 at the 
centrosomes [17].  Compelling evidence that CHFR ubiquitinates Aurora A was provided 
by Yu et al. in which they found that Aurora A was over-expressed in Chfr null mouse 
embryonic fibroblasts and tissues [8].  Additionally, using human cell lines they 
determined that the C-terminal cysteine-rich region of CHFR interacts with the N-
terminus of Aurora A by immunoprecipitation and that this interaction led to the 




Proteins Regulating Ubiquitination Activity 
Since CHFR has been described as an E3 ubiquitin ligase due to the presence of 
its RING domain, there must be E2 enzymes that it interacts with in order to function.  
CHFR has been shown to utilize the E2 ubiquitin-conjugating (Ubc) proteins Ubc4, 
Ubc5A, and Ubc5B in order to form Lys48-based polyubiquitin chains, but not E2 
enzymes UbcH7, UbcH8, or UbcH10 [5, 6].  CHFR has also been found to interact with 
the E2 enzyme complex Ubc13-MMS2 hetero-dimer to form lysine-63 linked 
polyubiquitin chains, which are associated with modifying protein function, not targeting 
them for degradation by the proteasome [5].  Both of these findings were recently 
confirmed in S. cerevisiae for the yeast orthologs of CHFR [28].  In addition to ubiquitin-
conjugating E2 enzymes, CHFR has been shown to interact with the deubiquitinating 
protein ubiquitin-specific protease 7 (USP7) by immunoprecipitation [29].  USP7 was 
found to deubiquitinate CHFR and inhibit its auto-ubiquitinating activity, thereby 
preventing the degradation of CHFR [29].  Interestingly, USP7 and CHFR both localize 
to PML bodies in the nucleus; in particular, CHFR has been shown to be in PML bodies 
in interphase cells [4, 29].         
Additional Interacting Proteins 
 Another potential interacting protein for CHFR is protein kinase B (PKB).  It was 
determined that PKB could phosphorylate CHFR on residues Thr39 and Ser208, 
potentially inhibiting the ubiquitin ligase activity of CHFR.  However, phosphorylation-
defective mutants of CHFR did not alter the checkpoint response to paclitaxel [16].  
Bothos et al. also found that CHFR was phosphorylated during mitosis, though they did 




CHFR and Cancer 
Mutations, Alternative Transcripts, and Chromosomal Aberrations 
CHFR has been implicated as a tumor suppressor in multiple cancers despite the 
fact that no heritable mutations in germline cells associated with a predisposition to 
cancer phenotypes have been identified and few mutations in somatic cancer cells have 
been described.  Though many groups have not been able to identify coding mutations in 
the CHFR gene, particularly in breast and colon cancers, several single-nucleotide 
polymorphisms (SNPs) have been identified [21, 30, 31].  However, three missense 
mutations in CHFR were found in primary non-small cell lung cancers, two mutations 
between the FHA and RING domains, and one in the cysteine-rich region, all three of 
which were unable to rescue the CHFR checkpoint in DLD-1 cells during nocodazole 
treatment [31].  However, even these mutations were rare events as they were only found 
in three patients, all of whom were smokers, out of 53 different patient samples tested 
[31].  Recently published data has indicated that one of these coding single nucleotide 
polymorphisms (SNPs), V539M (Accession No. NM_018223; V580M for Accession No. 
AF_170724) found within the C-terminal cysteine-rich region, was significantly 
associated with a lower risk of colorectoral cancer if the patient had the methionine 
amino acid instead of the valine [32].  This SNP was also strongly associated with the 
absence of metastases, TNM stage, and microsatellite instability, all of which indicate a 
favorable prognosis.  This variant was within the hap 10 (TGACTA) haplotype block that 
also contained the P138L SNP, which had correlated with the microsatellite instability 
phenotype [32].  Two additional deletion mutations have also been identified in which 
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either residues 135-146 were deleted between the FHA and RING domains or residue 
Ala470 was deleted in the C-terminal cysteine-rich region [31].  
Though they have not been studied extensively, alternative mRNA transcripts 
have been identified for CHFR.  Toyota et al. identified transcripts that were missing 
exons two, five, and/or six and the transcript missing exon two is believed to result in an 
isoform lacking the FHA domain (Figure 1.4) [3, 33].  This isoform was also found to be 
highly expressed in cancer cells when compared to matched normal tissues [33].  Though 
full-length CHFR was found to suppress cell growth when over-expressed, the FHA 
domain deletion mutant of CHFR was less effective in suppressing cell growth and had 
been previously identified as a dominant negative form of CHFR [3, 33]. 
CHFR is located at human chromosome 12q24.33, which is a site of allelic 
imbalance in many cancers.  Deletion of 12q24 was described in adenoid cystic 
carcinoma and as a prognostic indicator of recurrence in Wilm’s tumor and pituitary 
adenomas [34-36].  Band 12q24 also was associated with the presence of a metastasis 
suppressor gene, as amplification of 12q24 correlated with metastasis-free survival in 
breast cancer patients and decreased metastatic potential of prostate cancer cells [37-39].  
Further characterization of 12q24 would be required to determine if CHFR is the gene 
responsible for predicting cancer recurrence and metastasis in these association studies.        
CHFR Expression and Correlations with Clinico-Pathological Variables 
 Many studies have focused on studying the loss of CHFR mRNA expression due 
to promoter hyper-methylation in cancers compared to normal cells and tissues, and they 
are summarized in Table 1.1 [18, 19, 21, 30, 33, 40-64].  Although CHFR mRNA 






Figure 1.4: The chromosomal location and genomic structure of CHFR and its splice 
variants. 
 
CHFR is located at the distal end of human chromosome 12 at 12q24.33.  Full length 
CHFR consists of 18 exons and the start codon for translation is in exon two.  Splice 
variants of CHFR include one in which exon two is skipped, causing translation to begin 
in exon five and the deletion of the FHA domain (ΔFHA).  The other three splice variants 







promoter hyper-methylation only accounts for a percentage of these instances and is often 
tissue-dependent.  In particular, 16-53% of cancers of the gastro-intestinal tract have 
hyper-methylated promoters of the CHFR gene; however, this is extremely rare in 
gynecological cancers with the exception of HPV-positive cervical carcinomas [33, 47, 
59, 60, 63].  For example, 50% of breast cancer cell lines have decreased or lost CHFR 
expression compared to immortalized human mammary epithelial cells, but only 8% of 
the lines had a methylated promoter [21].  
 Altered mRNA expression of CHFR has been correlated with clinical and 
pathological variables (Table 1.1).  In particular, low or lost CHFR was associated with a 
high mitotic index in colorectal and breast cancers [21, 33].  A hyper-methylated CHFR 
promoter was also associated with advanced patient age, high tumor grade, advanced 
stage, poor differentiation, female gender, and taxane sensitivity [40, 42, 47, 48, 53, 56, 
58, 63].  Of these correlations, high mitotic index, advanced tumor stage, and taxane 
sensitivity have been replicated among different research groups [21, 33, 40, 42, 53, 58].  
Only a few studies recently have reported on the frequency of altered CHFR protein 
expression in cancers versus normal tissue.  Milne et al. found that 33% of gastric cancers 
were negative for CHFR expression by immunohistochemistry, which correlated with a 
diffuse histology [65].  Importantly, using immunohistochemistry CHFR localization to 
the nucleus was altered in 66% of malignant peripheral nerve sheath tumors.  In the same 
samples, decreased CHFR expression was associated with a multitude of clinical and 
pathological variables including young age, site of tumor to the trunk, head or neck, 
presentation of recurrent tumors, increased mitotic index, increased Ki67 staining for 
proliferation, abnormal karyotype, and poor patient prognosis [66].    
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Table 1.1: The frequency of CHFR promoter hyper-methylation and correlations 
with clinico-pathological variables. 
 
a methylation-specific PCR (MS-PCR), b 5-aza-dC treatment, c combined bisulfite 
restriction analysis (COBRA), d bisulfite sequencing, e CpG island microarray, f 
methylation-specific multi-plex ligation-dependent probe amplification (MS-
MLPA), g MethyLight quantitative methylation-specific PCR 
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CHFR is a Tumor Suppressor and Regulator of Genomic Stability 
 The first indication that CHFR was a potent tumor suppressor was the creation of 
the Chfr knockout mouse, which was viable with no developmental defects [8].  A small 
percentage (9%) of these mice developed lymphomas by 40 weeks of age and later they 
were prone to developing spontaneous cancers of epithelial origin, primarily lung, liver 
and gastro-intestinal tumors.  Fifty percent of the knockout mice also developed skin 
tumors following treatment with the chemical carcinogen dimethylbenz(a)anthracene 
(DMBA) at four months of age compared to none of their wild-type littermates [8].  
There was also indication that the loss of Chfr led to cellular transformation because 
embryonic fibroblasts from the mice were able to form colonies in culture [8].  
Interestingly, Chfr was found to be important for maintaining genomic stability in the 
embryonic fibroblasts from the Chfr null mice.  About 30% of the cells became aneuploid 
after four passages likely due to several mitotic defects that were observed, which 
included lagging anaphase chromosomes, failed nuclear segregation and failed 
cytokinesis, resulting in 17% of the cells becoming multi-nucleated [8].  Of interest, they 
discovered that down-regulating Aurora A by RNAi rescued the genomic instability 
phenotype in Chfr null mouse embryonic fibroblasts [8]. 
CHFR as a Potential Biomarker for Chemotherapeutic Response to Taxanes 
 As indicated above and in Table 1.1, CHFR promoter hyper-methylation was 
previously shown to correlate with taxane sensitivity in gastric cancers and cervical 
carcinomas [40, 53].  In support of these findings, cultured cells that were transfected to 
over-express CHFR showed a decrease in apoptotic response to taxanes and enhanced 
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cell survival, whereas decreasing CHFR by RNAi resulted in enhanced sensitivity (ie: 
increased apoptotic response) to taxanes [3, 18-20].  These reports have indicated that the 
CHFR expression status of cancers might be an excellent biomarker for tumor response 
to taxane treatment.  However, this poses a very interesting dichotomy for CHFR 
expression.  On one hand, losing the potential tumor suppressive functions of CHFR may 
lead to cancer, whereas on the other hand, an absence of CHFR expression might actually 
be favorable as it would be a positive indicator of chemotherapeutic response to taxane 
treatment.  Future work studying the potential role of CHFR as a biomarker for 
chemotherapeutic response to taxanes in diverse tissues, and the mechanism of this 
response, would definitely be valuable both at the bench and at the clinic.     
 CHFR is a novel mitotic checkpoint protein and potential biomarker for 
chemotherapeutic response to taxanes.  Its expression also is frequently altered in many 
types of cancer and the null mouse is cancer-prone.  These facts led to the hypothesis that 
CHFR is biologically relevant to the pathogenesis of human breast cancer and functions 
in the maintenance of genomic stability.  To test this hypothesis, the first aim of this work 
was to define the relevance of CHFR expression to breast cancer pathogenesis in cell 
lines and primary tissues from mammary epithelium and the findings from these 
experiments are presented in Chapter 2.  The second aim, which is described in Chapter 
3, was to characterize the phenotypic effects of altering CHFR expression in cell culture 
models of breast cancer.  Chapter 4 describes the findings from the third aim, which was 
to determine if CHFR has a role in maintaining genomic stability.  Chapter 5 is a 
concluding chapter that discusses the significant findings of this thesis and potential 









In recent years, there has been increasing evidence supporting the role of CHFR 
as a tumor suppressor, most of which report loss of mRNA expression in cancers 
compared to patient-matched normal tissues.  This altered CHFR expression is 
occasionally due to promoter hyper-methylation, but other modes of lost expression have 
not been identified.  However, mRNA expression does not always correlate with the 
functional protein expression due to post-transcriptional and post-translational regulation 
and modifications.  Therefore, we studied both a panel of breast cancer cell lines as well 
as primary tissue samples from breast cancer patients for CHFR protein expression, using 
Western blotting and immunohistochemistry, respectively, to determine if expression was 
altered in breast cancers compared to normal mammary tissue.  CHFR protein expression 
was low or lost in approximately 40% of both primary and cultured breast cancers, 
though when Western blotting was compared with quantitative RT-PCR to detect mRNA 
from cultured cells, fewer cell lines showed lost expression at the mRNA level.  This 
discrepancy between mRNA and protein expression suggested that post-transcriptional or 





 Frequently, genes that are relevant to tumorigenesis are not properly expressed in 
cancer cells when compared with normal tissues or immortalized, non-tumorigenic cell 
lines, an example of which is CHFR.  In particular, a previous report from our lab 
showed that decreased CHFR mRNA expression occurred in 50% (12 of 24) of the 
cultured breast cancers tested by Northern blot analysis (Figure 2.1) [21].   
 Although many studies have focused on examining CHFR mRNA expression, 
typically with non-quantitative methods, this is not always a good indicator of functional 
protein expression and for studying correlations between gene expression and cellular 
phenotypes or clinico-pathological variables.  This is because many expressed genes 
undergo post-transcriptional regulation to control protein expression [67].  For example, 
cells can adjust mRNA translation via phosphorylation of eukaryotic initiation factor-
2α or by regulating other components of the translation machinery [68].  Many known 
growth signal transduction pathways that are deregulated in cancer cells, such as Ras, 
MAPK, and m-Tor, activate components of the translational machinery whereas, on the 
contrary, tumor suppressor proteins such as p53 and pRb are normally required to limit 
ribosomal and tRNA synthesis to inhibit translation [69].  
Another mechanism of post-transcriptional regulation is through the RNAi 
pathway.  In particular, micro RNAs (miRNAs) can quickly change protein expression in 
response to the environment by causing transcript degradation or by inhibiting the 
ribosome and additional proteins of the translational machinery from binding to the 
transcript [70].  There is abundant evidence that this mechanism of post-transcriptional 
regulation can be disrupted in cancers.  These small RNAs, if over-abundant, could cause 
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excessive down-regulation of important tumor suppressors whereas the lack of miRNA 
production could allow the over-expression of oncogenes [71].  In addition, a group of 
miRNAs were recently found to be transcriptional targets of the key tumor suppressor 
protein p53; therefore, if p53 is mutated or nonfunctional in cancers, the downstream set 
of regulatory miRNAs, miR-34, that can control apoptosis and cell cycle arrest would 
also be lost [72].  Therefore, post-transcriptional regulation is a target for alteration 
during tumorigenesis.  This evidence clearly indicates that the regulation of mRNA 
translation may frequently be altered in cancer cells compared to normal cells, making it 
unlikely that measures of mRNA expression would agree with protein production. 
Although many studies have focused on CHFR mRNA expression, a more 
informative analysis would be to study protein expression.  Therefore, this work focused 
on assessing CHFR protein expression in cultured and primary breast cancers.  We 
hypothesized that CHFR protein expression would be altered in breast cancers compared 
to normal tissue or non-tumorigenic immortalized cell lines.  To test this, CHFR 
expression was analyzed by quantitative RT-PCR and Western blotting in cultured breast 
cancer cells and immortalized human mammary epithelial cells (IHMECs) and by 
immunohistochemistry in primary breast tissue.  CHFR expression was frequently lost or 
low in breast cancers, which correlated with a high mitotic index.  There was a 
discrepancy between mRNA and protein levels in some cell lines, suggesting that post-






Figure 2.1: CHFR expression is low or lost in 50% of breast cell lines by Northern 
blot analysis. 
 
Northern blotting using a probe for the central region of CHFR indicated that 50% (12 of 
24) breast cell lines, not including the IHMEC line HPV5-24 used as a positive control, 
had low CHFR expression as indicated by an asterisk (*).  MCF10A is another non-
tumorigenic IHMEC line whereas the remaining samples are breast cancer cell lines.  A 
probe for GAPDH was used as a loading control [21].   
 
 





Materials and Methods 
Cell Culture 
Most cell lines were obtained from the American Type Culture Collection 
(AATC, Manassas, VA) and grown under recommended conditions.  SUM1315, 
SUM102, SUM190, SUM159, SUM149, SUM52, SUM185, SUM225, SUM229, and the 
human papilloma virus (HPV)-immortalized series of non-tumorigenic immortalized 
human mammary epithelial cell (IHMEC) lines were developed and provided by S.P. 
Ethier  (now available from Asterand) and cultured according to specified conditions 
[73].  A detailed description of relevant cell line information, including origins and 
hormone receptor status, has been compiled by Neve, R.M. et al [74].  For cell 
synchronization, 1x106 cells were plated in a 100 mm dish and exposed to 2 mM 
thymidine for 12 hours, released into fresh media for 10 hours, then treated with another 
round of 2 mM thymidine for an additional 12 hours.  Cells were then collected at the 
point of synchronization or released into fresh media for 4-10 hours to allow continuation 
into the S and G2/M phases of the cell cycle.     
 
RT-PCR  
For semi-quantitative duplex RT-PCR, reaction conditions were optimized as 
previously described [75].  Briefly, primer concentrations were optimized to create equal 
band intensity between CHFR and the internal GAPDH loading control, and the cycle 
number that resulted in the logarithmic phase of product generation was determined.  
Total RNA was isolated from cultured cell lines via the Qiagen RNeasy RNA isolation 
kit.  cDNA was then generated from 1.0 μg of total RNA using the Qiagen Omniscipt 
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Reverse Transcription kit (Qiagen Inc.) and random hexamer primers.  CHFR cDNA was 
amplified with the primers (forward/reverse, 5’-3’):  
CAGCAGTCCAGGATTACGTGTG/AGCAGTCAGGACGGGATGTTAC (500 bp) and 
GAPDH cDNA was amplified with the following primers (forward/reverse, 5’-3’): 
AGTCCATGCCATCACTGCCA/GGTGTCGCTGTTGAAGTCAG (340 bp).  PCR 
products were separated on a 1.0% agarose gel in 1x TBE and stained with ethidium 
bromide.  Band intensity was assessed using the IS-1000 Digital Imaging System (Alpha 
Innotech Corp). 
For quantitative RT-PCR, cDNA samples from IHMECs and breast cancer cell 
lines were amplified in triplicate from the same total RNA sample following the 
manufacturer’s instructions.  Samples were amplified using TaqMan MGB FAM dye-
labeled in an ABI7900HT model Real-Time PCR machine (Applied Biosystems).  To 
amplify CHFR cDNA, probe set Hs00217191_m1 was utilized while the control, 
GAPDH, was amplified with probe set Hs99999905_m1 (Applied Biosystems).  CHFR 
expression was considered low if it was less than the range of expression observed in 
immortalized epithelial cells. 
 
Western Blotting 
Whole cell lysates were collected according to manufacturer’s instructions with 
the M-Per Mammalian Protein Extraction Buffer and HALT protease inhibitor cocktail 
with EDTA (Pierce) and the concentrations were quantified using the Bradford assay.  To 
assess CHFR protein levels, 60.0 μg of total protein from 70-80% confluent cell cultures 
was separated on 10% SDS-PAGE gels using the Criterion or Ready gel systems (Bio-
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Rad Laboratories) and immunoblotted to Hybond-P PVDF membrane (Amersham 
Biosciences).  Following one hour of incubation in a blocking solution of 2.5% non-fat 
dry milk and 0.1% TBS-Tween20, a monoclonal antibody against CHFR (Abnova) was 
used at a 1:500 dilution in 2.5% non-fat dry milk and 0.05% TBS-Tween20 and 
incubated overnight at 4°C.  CHFR was detected by hybridization with a goat anti-
mouse:HRP secondary antibody (Cell Signaling Technology) at a 1:2000 dilution in 2.5% 
non-fat dry milk and 0.05% TBS-Tween20.  For a loading control, blots were blocked in 
5% non-fat dry milk and 0.1% TBS-Tween20 for one hour.  The blots were then stripped 
and immunoblotted again with an antibody against GAPDH as a control.  The anti-
GAPDH antibody (Abcam) was used at a 1:10,000 dilution and detected with a goat anti-
mouse:HRP antibody at a 1:15,000 dilution, both in 5% non-fat dry milk and 0.05% 
TBS-Tween20.  The Super Signal West Pico Chemiluminescent kit (Pierce) was used for 
detection and blots were exposed to Kodak Biomax XAR film.  Relative expression of 
CHFR was assessed by using the IS-1000 Digital Imaging System (Alpha Innotech Corp) 
for densitometry to determine signal intensity, then a ratio of CHFR:GAPDH  or 
CHFR:β-Actin was calculated.  CHFR expression was considered low if the ratio of 
relative expression was less than the range of expression observed within the 
immortalized epithelial cell lines. 
 
Mitotic Index 
Cells were collected at 70% confluence by trypsinization and resuspended in 
0.075 M KCl on ice for 30 minutes.  Cells were fixed in a 3:1 mixture of methanol and 
glacial acetic acid with mild vortexing, dropped onto glass slides, and stained with 544 
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μg/ml Giemsa solution.  The mitotic index was calculated as the percentage of cells with 
condensed chromosomes.  Nine hundred cells were counted on average for each cell line.  
Mitotic indices were calculated based on the percentage of cells that were in any stage of 
mitosis with visibly condensed chromosomes as analyzed by light microscopy.  Mitotic 
indices less than 50% were considered “low,” whereas indices more than 50% were 
considered “high.”   
 
Flow Cytometry 
Cells were collected by trypsinization and pelleted, then washed in 1x PBS.  
Pelleted cells were fixed by the dropwise addition of ice-cold 100% ethanol and 
resuspended with mild vortexing.  The ethanol was then aspirated off following 
centrifugation, and the cells were resuspended in 500 μl of 50 μg/ml propidium iodide 
and 100 μg/ml RNase in 1x PBS and analyzed by flow cytometry. 
 
Tissue Samples and Immunohistochemistry 
The monoclonal anti-CHFR antibody was used at a 1:50 dilution for hybridization 
to paraffin-embedded sections of human breast tissue using standard methods.  Primary 
antibody was detected following protocols described by the manufacturer 
(DAKOCytomation,), using diaminobenzidine as a chromogen and with Harris 
Hematoxylin counterstain (Surgipath Medical Industries).  Optimization and validation of 
the immunostaining conditions was performed on multi-organ tissue microarrays using a 
DAKO Autostainer.   
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To study CHFR expression in primary breast cancers, 160 paraffin-embedded 
patient samples arrayed on a single high density tissue microarray (TMA) were used for 
the analysis [76].  Details on this TMA have been previously described [77].  Tissue 
cores from 98 patients with invasive breast carcinoma were available to evaluate CHFR 
staining.  The staining was scored using a 4 tiered scoring system (1=negative, 2=weak, 
3=moderate, 4=strong) by two independent trained investigators in the Department of 
Pathology (Celina Kleer, MD and Lei Ding.) and ChromaVision computerized scoring 
(Clarient Inc.).  To determine CHFR staining in normal mammary epithelia, paraffin-
embedded tissues from patients were prepared as above.  Digital images were obtained 
with an Olympus BX-51 microscope and SPOT camera system at either a 40x or 60x 
objective magnification.  Images of normal breast samples were recoded at a 20x 
objective magnification.   
 
Statistical Analysis 
The Wilcoxon rank test was used to determine if there was an association between 
CHFR staining and clinico-pathological variables including patient age, tumor size, 
tumor grade, lymph node status, estrogen receptor (ER), progesterone receptor (PR), 
HER2/neu status, and patient survival.  The Chi-square test, using a 2 x 2 contingency 
table, was used to test for statistical significance when comparing CHFR expression by 







CHFR mRNA Expression in Breast Cancer Cell Lines 
Previous reports indicated that CHFR mRNA was low in 50% of breast cancer 
cell lines as assessed by Northern blot analysis [21].  In this study, quantitative RT-PCR 
was employed to better define the levels of CHFR mRNA from asynchronous breast 
cancer cell lines compared to IHMECs.  mRNA was collected from cells at 70-80% 
confluency, the same confluency previously used for Northern blot analysis.  Quantitative 
RT-PCR was performed using a probe that hybridized to exons 12 and 13, which is near 
the middle of the probe previously used for Northern blot analysis.  Quantitative RT-PCR 
revealed that only 18% (four of 22) of breast cancer cell lines showed CHFR expression 
levels lower than the range of expression observed in HPV-immortalized IHMECs 
(Figure 2.2).  These four cell lines, CAL51, DU4475, Hs578T, and SUM229, were also 
found to have low or lost CHFR expression by Northern blot analysis [21].  In addition, a 
spontaneously immortalized IHMEC line, MCF10A, was also found to have low CHFR 
mRNA expression by both Northern blotting and quantitative RT-PCR.  
 
Low CHFR Expression in Breast Cancer Cell Lines Correlates with a High Mitotic 
Index 
Western blotting was performed to assess CHFR expression in breast cancer cell 
(BCC) lines and immortalized human mammary epithelial cell (IHMEC) lines.  Variable 
expression was noted among the breast cancer cell lines.  Densitometry analysis revealed 
that 41% (9 of 22) of asynchronous breast cancer cell lines appeared to have low or no 






Figure 2.2: CHFR mRNA expression is low in 18% of breast cancer cell lines by 
quantitative RT-PCR. 
 
Quantitative RT-PCR, using a probe that spanned exons 12 and 13 of the CHFR 
gene, indicated that 18% (four out of 22) breast cancer cell lines and the MCF10A 
IHMEC line (white bars) had low CHFR expression.  Low expression was characterized 
as a ratio of CHFR to GAPDH lower than that observed in the range of HPV-
immortalized IHMEC cells (< 0.7).  The remaining cell lines (black bars) either had 
CHFR expression within the range of HPV-immortalized IHMECs (in bold) or were 








IHMEC cell lines, whereas only one cell line, MDA-MB-157, had expression higher than 
the range observed in IHMEC cells (Figure 2.3).  This cell line also had highly 
upregulated mRNA expression as determined by quantitative RT-PCR (Figure 2.2).  The 
remaining lines had expression levels that fell within the range of IHMEC cells. 
The previously published mitotic indices of the breast cancer cell lines and two 
IHMEC lines, MCF10A and HPV4-12, were graphed and organized according to CHFR 
protein expression (Figure 2.4) [21].  There was a statistically significant correlation 
between CHFR protein expression and mitotic index following nocodazole treatment 
(p<0.001, Chi-square test).  It became apparent that all of the cell lines that were 
determined to have low or no CHFR protein expression had high (>50%) mitotic indices.  
Of the remaining breast cancer cell lines, 62% had CHFR expression similar to the 
IHMEC lines and low mitotic indices and the two IHMEC lines had low mitotic indices.  
Only five breast cancer cell lines with “high” CHFR expression (i.e.: similar to the 
expression observed in IHMECs) had an uncharacteristically high mitotic index, which 
may be due to any number of mutations or alterations that could impair the poorly 
characterized CHFR-mediated prophase checkpoint pathway or other pathways. 
 
CHFR Protein is Present During the S and G2/M Phases of the Cell Cycle 
 In order to test if CHFR protein expression was cell cycle regulated a series of 
breast cancer and IHMEC lines were synchronized with a double-thymidine block and 
released into fresh media.  Cells were collected periodically for both whole cell lysates 
and for analysis by flow cytometry to determine their cell cycle profile.  CHFR 








Figure 2.3: CHFR protein expression is low or lost in 41% of breast cancer cell lines 
by Western blotting. 
 
Western blot analysis using a monoclonal CHFR antibody reveals that 9 of 22 (41%, 
underlined) asynchronous breast cancer cell lines, or BCCs, at 70-80% confluence have 
low CHFR expression compared to the lowest level of expression observed among four 
asynchronous immortalized human mammary epithelial cells (IHMECs).  To control for 
loading, an antibody against GAPDH was used (bottom).  This figure is a composite 
image of two separate Western blots.  Whole cell lysate from the MCF10A IHMEC line 








Figure 2.4: Low CHFR protein expression correlates with a high mitotic index in 
breast cancer cell lines. 
 
The mitotic index of breast cancer cell lines and two IHMEC lines (bold) were plotted 
and arranged according to whether they were “low” or “high” CHFR expressing lines.  
High expressing cell lines are those in which CHFR expression was determined to be 
within the range observed in IHMEC lines by Western blotting.  The mitotic index was 
considered high if it was greater than 50%.  Cells were treated with nocodazole and 
mitotic indices were determined, following Giemsa staining of dropped slides, based on 
the percentage of cells with condensed chromosomes.  There was a statistically 








contamination with S phase cells.  The synchronization process was inefficient for G1 
phase enrichment as some lines had nearly equal percentages of G1 and S cells following 
the double-thymidine block.  There was better enrichment for cells in the later stages of 
the cell cycle following release into fresh medium.  CHFR was expressed at least during 
the S and G2/M phases of the cell cycle in the IHMEC cell lines HPV4-12 and MCF10A, 
supporting its role as a mitotic checkpoint protein (Figure 2.5).  Of note, two of the four 
breast cancer cell lines, CAL51 and Hs578T, either did not express CHFR at all or 
actually had lower CHFR expression during the G2/M phases than the G1 and S phases.  
Both of these cell lines were characterized as having low or no CHFR expression by 
Western blotting, as indicated above, and a high mitotic index that signified an impaired 
CHFR-mediated prophase checkpoint. 
 
CHFR Expression in Primary Breast Cancers 
 As expected, CHFR staining by immunohistochemistry was prominent in the 
cytoplasm of mammary gland epithelial cells from normal primary breast tissue (Figure 
2.6).  We also found prominent nuclear staining of CHFR in some cells of the epidermis 
near the edge of the biopsy sample, indicating that CHFR may translocate to the nucleus 
in rapidly dividing cells and tissues, which was supported by the fact that this was also 
observed in primary intestinal and testicular tissue (Figure 2.7, and data not shown).  We 
next wanted to determine if CHFR expression was altered in primary breast cancers.  
From 160 patient samples of invasive breast carcinoma present on a tissue microarray 
(TMA), 142 were available to score for CHFR staining.  Of the 142 patient samples of 











Figure 2.5: CHFR expression is present at least during the S and G2/M phases of the 
cell cycle in most breast cell lines studied. 
 
Cell lines were synchronized at the G1/S transition with a double-thymidine block (G1) 
and then released in to fresh medium for 4-10 hours to enrich for S and G2/M phase cells.  
Cells were analyzed following propidium iodide staining by flow cytometry to determine 
the DNA content, which indicated cell cycle stage.  The percentage of cells in each phase 
of the cell cycle is indicated below the sample.  Western blotting was performed to 















Figure 2.6: CHFR is expressed in the mammary gland epithelial cells from normal 
breast tissue. 
 
Immunohistochemistry for CHFR protein expression showed prominent staining in the 
cytoplasm of the mammary gland epithelia in normal primary breast tissue samples.  
Representative examples are indicated by three separate patient tissues: KID332, 
















Figure 2.7: Immunohistochemistry for CHFR shows prominent nuclear and 
cytoplasmic staining in skin cells and stromal cells. 
 
Immunohistochemistry for CHFR protein expression showed prominent staining in the 
nuclei and lighter staining in the cytoplasm of epidermal skin cells at the edge of the 









showed strong CHFR staining.  The number of patient samples per staining score are as 
follows: negative (1), 51; weak (2), 35; moderate (3), 48; and strong (4), 8 (Figure 2.8). 
 
CHFR Expression Correlates with Clinical and Pathological Variables 
Immunohistochemistry was performed on a tissue microarray that consisted of 
160 tissue samples of primary invasive breast cancers.  Of the 160 samples, 98 had 
complete clinico-pathological data for statistical analysis.  The staining for CHFR 
expression was scored using a 4-tiered scoring system (1=negative, 2=weak, 3=moderate, 
4=strong).  Patient samples were annotated for several clinico-pathological variables 
including: tumor size, estrogen receptor (ER) status, progesterone receptor (PR) status, 
HER2/neu expression, lymph node status, patient age, and tumor grade.  Primary samples 
were classified as positive for CHFR staining and expression if they scored between two 
and four in staining intensity.  Since there is no published evidence as to a threshold of 
expression that is required for proper CHFR function, we included all positively stained 
samples in our analysis.  Interestingly, there was a trend towards positive CHFR staining 
being correlated with ER-positive tumors (p=0.0903 by Wilcoxon rank test, p=0.0653 by 
t-test; Table 2.1).  There was a striking significant correlation between positive CHFR 









Figure 2.8: CHFR staining is negative in 36% (51 of 142) of primary invasive breast 
cancers as determined by immunohistochemistry. 
 
Immunohistochemistry using a monoclonal antibody against CHFR on primary invasive 
breast cancers from a tissue microarray shows a range of CHFR expression.  Intensity of 
CHFR staining ranged from negative (1) to weak (2), moderate (3), and strong (4).  The 
images on the top are at 10x magnification whereas the corresponding pictures on the 





Table 2.1: Correlation of CHFR expression with clinical and pathological variables 
from 160 patient samples.  
 
  









Prior to this work, many studies focused on the expression profiles of CHFR 
mRNA, but results indicating possible correlations with clinical and pathological 
variables were contradictory.  This may be because mRNA expression does not always 
reliably predict protein levels, due to processes such as post-transcriptional regulation.  
Therefore, in this report we analyzed CHFR protein expression then compared it to 
current and previous reports of mRNA expression levels to assess if mRNA detection 
could predict protein expression, and determined if protein expression correlated with 
clinical and pathological data in both cultured and primary breast cancers.   
When the mRNA expression data from the quantitative RT-PCR was compared to 
the previously published Northern blot data (Figure 2.1), there were six breast cancer cell 
lines in which the mRNA expression levels were not consistent between the two methods.  
These lines were considered low by Northern blotting but were within the range of 
expression observed in IHMEC lines by quantitative RT-PCR.  These cell lines were 
BT20, SUM52, SUM159, SUM149, MDA-MB-468, and MDA-MB-361.  However, for 
three cell lines, the low expression level identified by Northern blotting matched that 
observed by Western blotting (BT20, SUM159, and MDA-MB-361) and, in agreement 
with CHFR’s role in regulating mitotic entry, all three of these cell lines were previously 
determined to have a high mitotic index following nocodazole treatment.  The other three 
cell lines (SUM52, SUM149, and MDA-MB-486) were found to have CHFR mRNA 
expression similar to the levels observed in IHMEC lines by quantitative RT-PCR, which 
was confirmed by Western blotting.  Only one of these cell lines, MDA-MB-468, was 
previously determined to have the expected low mitotic index following nocodazole 
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treatment that has been associated with positive CHFR expression.  The other two lines, 
SUM52 and SUM149, still had uncharacteristically high mitotic indices despite having 
CHFR expression levels similar to IHMECs, which may be due to a different impaired 
protein in the CHFR-mediated prophase checkpoint pathway.  
The difference between Northern blot analysis and quantitative RT-PCR may be a 
result of the much higher sensitivity of quantitative RT-PCR to low amounts of sample or 
perhaps some transcripts were more easily detected by the quantitative RT-PCR probe in 
comparison to the probe used for Northern blotting.  In addition, the arbitrary and non-
quantitative identification of cell lines with “low” CHFR expression by Northern blot 
analysis, without the use of immortalized lines or mRNA from normal mammary tissue 
as a guide for what constitutes “normal” CHFR expression, lends itself to the 
mischaracterization of cell lines in terms of their expression levels.  However, when the 
two mRNA detection methods are combined, the results resemble the relative expression 
observed by Western blotting.  Cell lines with “normal or high” mRNA levels tended to 
have “normal or high” protein expression that resembled that seen in IHMECs, and vice 
versa.  In conclusion, a single method of detecting mRNA expression was not sufficient 
to predict the amount of protein detected by Western blotting.           
There were three cell lines, MDA-MB-231, SKBr3, and MCF10A, in which the 
CHFR mRNA levels agreed between the Northern blot and the quantitative RT-PCR, but 
the protein expression identified by Western blotting did not agree with the mRNA 
expression.  Both MDA-MB-231 and SKBr3 were determined to have “high” CHFR 
mRNA expression but were found to have very low protein expression by Western 
blotting when compared to IHMECs.  Interestingly, both of these cell lines had a high 
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mitotic index, which agrees with their classification as “low” expressing lines by Western 
blotting.  The spontaneously immortalized IHMEC line, MCF10A, was found to have 
low CHFR mRNA expression using both methods, but Western blotting revealed that it 
actually expressed CHFR protein at levels similar to the other IHMEC lines, which 
agreed with the finding that it had a low mitotic index.   
The lack of a direct correlation between mRNA levels and protein expression 
suggested that CHFR might be regulated by post-transcriptional or post-translational 
modifications.  Previous studies have shown that CHFR auto-ubiquitinates and that it 
might be phosphorylated [5, 7, 16].  A recent publication also indicated that CHFR could 
be modified by poly(ADP-ribosyl)ation, which is the addition of long chains of ADP-
ribose [9].  These modifications and perhaps others might begin to explain the differences 
between mRNA and protein expression levels due to changes in protein stability.  In 
support of this, our lab and others have found that antibodies against CHFR occasionally, 
but not always, identify a second band; however, the identity of this band or the 
modification of CHFR that leads to the size differential has not been determined.  The 
different band sizes may be due to the presence of alternative transcripts or protein 
modifications such as phosphorylation, ubiquitin conjugation, or poly(ADP-ribosyl)ation.   
Attempts to identify when CHFR was expressed during the cell cycle using a 
double-thymidine block synchronization method indicated that CHFR was expressed 
during the S and G2/M phases of the cell cycle.  Detection of CHFR during the G1 phase 
was difficult to interpret due to the inefficiency of the synchronization method.  Further 
studies are required to identify how CHFR expression is regulated and when it is 
expressed during the cell cycle. 
45 
 
We noticed that the frequency of low or lost CHFR expression by Western 
blotting and immunohistochemistry (approximately 40%) was much greater than the 
incidence of CHFR over-expression or strong staining, which was 4.5% and 5.6%, 
respectively, in breast cancers.  Of interest, during the course of this work we attempted 
to over-express CHFR in several mammary epithelial cell lines, both cancer and non-
tumorigenic lines, using both transient and stable transfection and retroviral transduction 
methods, but nearly all attempts resulted in cellular toxicity.  This suggested that the 
expression of CHFR must be tightly regulated such that too little may contribute to 
tumorigenesis but over-expression, which rarely occurs, may lead to cell death in many 
genetic backgrounds. 
The frequency of low or lost expression in breast cancer cell lines (41%) was very 
comparable to the occurrence of lost expression in primary invasive breast cancers 
(36%).  This suggests that the breast cancer cell lines are good models for studying the 
mechanisms and results of lost CHFR expression.  It is interesting to note that had the 
category of “weak” CHFR expression by immunohistochemistry been included in the 
calculations, then nearly 61% of primary invasive breast cancers would have been 
considered to have “low or lost” CHFR expression.  This is a staggeringly high number, 
which indicates that loss or down-regulation of CHFR protein expression may be a very 
common occurrence in breast cancers.  The samples in this category obviously had less 
intense staining when compared to the intensity of CHFR staining in the three normal 
mammary tissue samples shown.  However, because the threshold of the amount of 
CHFR necessary for proper cellular function has not been determined, we had to include 
this group along with the “moderate” and “strong” expression groups.  
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In regards to primary invasive breast carcinoma, the correlation between CHFR 
staining and small tumor size, a very important prognostic indicator, is remarkable and 
supports a role for CHFR as a tumor suppressor.  In addition, the putative association of 
CHFR and ER expression may provide continued support of a role for CHFR as a 
biomarker for breast cancer treatment.  This is particularly relevant given previous 
clinical trials that showed ER-positive, and therefore possibly CHFR-positive, breast 
cancers did not respond as well to paclitaxel treatment as ER-negative breast cancers [78-
80].   This corresponds well with previously published work describing CHFR-negative 
cells as sensitive to microtubule poisons in culture, undergoing apoptosis sooner than 
their CHFR-positive counterparts.  The weak association of expression between ER and 
CHFR also may help to elucidate another molecular pathway in which CHFR functions 
to mediate cell proliferation or a common means of gene expression regulation. 
The frequency of decreased CHFR expression indicated that loss of expression 
was biologically relevant for tumorigenesis.  It also was noted that low CHFR protein 
expression strongly correlated with a high mitotic index, indicating that CHFR may play 
an important role in regulating mitotic entry and/or proliferation.  Of particular 
importance, the loss of CHFR expression strongly associated with the important 
pathological variable, and prognostic indicator, of large tumor size.  When combined, 
these results suggest that CHFR may be a cancer-relevant protein with important tumor 
suppressive functions.  In addition, the data indicate that a single method of detecting 
CHFR mRNA does not reliably predict protein expression, and that protein levels of 
CHFR can be used to identify correlations between expression and clinical and 
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ALTERED EXPRESSION OF CHFR IN MAMMARY EPITHELIAL CELLS: 




CHFR (Checkpoint with FHA and Ring Finger) is hypothesized to mediate a 
delay in cell cycle progression, early in mitosis, in response to microtubule stress, 
independent of the spindle assembly checkpoint.  As a potential regulator of cell cycle 
progression, CHFR naturally becomes an interesting target for understanding cancer 
cells.  In recent years, there has been increasing evidence supporting the role of CHFR as 
a tumor suppressor, most of which reports loss of expression, occasionally due to 
promoter hyper-methylation, in cancers compared to patient-matched normal tissues.  To 
study the effects of low CHFR expression in vitro, we stably expressed a shRNA 
construct targeting CHFR in two lines of immortalized human mammary epithelial cells 
(IHMECs).  Notably, decreased CHFR expression resulted in the acquisition of many 
phenotypes associated with malignant progression including accelerated growth rates, 
higher mitotic index, enhanced invasiveness, increased motility, greater aneuploidy, and 
amplified colony formation in soft agar.  In complementary studies, over-expressing 
CHFR in the Hs578T breast cancer cell line abrogated several tumorigenic phenotypes in 




Breast cancer is caused by changes in gene expression or function that result in 
normal mammary epithelial cells growing uncontrollably and sometimes becoming able 
to metastasize to distant sites.  Some of the characteristics that differentiate a cancer cell 
from a normal cell are that they become self-sufficient for growth signals, insensitive to 
anti-growth signals, they can evade apoptotic cell death, they have limitless replicative 
potential (i.e.: they are immortalized), they can promote angiogenesis, they can invade 
surrounding tissue to metastasize, and genomic instability often occurs [81].  The genes 
that affect these characteristics can be classified either as tumor suppressors or as 
oncogenes.  Tumor suppressor genes are needed to decrease growth rates, maintain cell 
morphology and polarity, activate an apoptotic response, prevent genomic instability, and 
impede cellular invasion and motility to inhibit metastasis.  On the contrary, oncogenes 
promote tumorigenesis by increasing growth rates, changing cellular morphology and 
polarity, deactivating the apoptotic response pathways, promoting genomic instability, 
and enhancing the invasive potential and motility of a cell to promote metastasis [81].  
The expression of tumor suppressor genes is often down regulated in cancers or the 
protein becomes non-functional whereas oncogenes are typically over-expressed or 
functionally hyperactive in cancers compared to normal cells.  However, for cancer to 
develop a combination of tumor suppressor loss and the gain of activated oncogenes is 
required [81]. 
Several methods can be used both in cell culture and by analyzing primary breast 
cancer tissue to determine if a gene has a role in regulating tumorigenesis.  Though many 
assays themselves do not predict if a cell is tumorigenic, they can suggest that the cell has 
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phenotypically changed to resemble a cancer cell.  As an example, the growth rate of the 
cell population can be measured by manually counting cells over the course of several 
days.  However, changes in growth rates can be caused by either increased cellular 
proliferation (“self-sufficiency of growth signals”) or decreased cell death by apoptosis 
[82].  Therefore, methods to monitor cellular metabolism or cell death are required to 
determine the causes of altered population growth rates.  One method to test whether or 
not potentially cancerous cells have the ability to metastasize is through a chemo-
invasion assay using a Matrigel collagen matrix to model the basement membrane of 
tissues, and by measuring cellular motility into surrounding empty spaces in a culture 
plate [83].  The chemo-invasion Matrigel assay tests if cells can migrate through the 
collagen matrix in order to reach a growth factor or chemoattractant.  Cellular 
morphology and polarity changes can be noted by visual inspection of cell shape and by 
assessing protein marker expression that is characteristic of particular cell types.  
Likewise, genomic instability can be tested by manually counting the chromosomes on 
slides prepared from metaphase cells.  The final cell culture method to assess 
tumorigenicity is to determine if cells have the ability to grow in colonies in a soft agar 
suspension, indicating they have lost cell-to-cell contact inhibition and have acquired 
anchorage-independent growth [84].  In addition to cell culture models, another means of 
determining if a cell has become tumorigenic is to inject the cells into immuno-
compromised mice to determine if tumors are able to form in vivo [85].   
Primary cancer tissue can be characterized by its visible difference from normal 
tissue when analyzed with a microscope.  Primary malignant cancers will have lost tissue 
organization and will appear as a mass of unorganized cells, with possible evidence of 
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invasion into surrounding normal tissue and stroma.  Diagnostic and prognostic 
information is gathered by looking for protein markers for proliferation, such as Ki67, 
and other defining characteristics such as the presence of estrogen and progesterone 
hormone receptors in breast cancer and aneuploidy [86].  Further characterization of 
cancer is done by staging the cancer according to tumor size and the presence or absence 
of metastasis; early stage cancers have small tumor sizes of less than two centimeters and 
no metastatic lesions [87].     
To characterize the role of CHFR in breast cancer, we used both cultured breast 
cell lines and primary patient samples.  Analysis of a tissue microarray composed of 
primary invasive breast cancer samples by immunohistochemistry indicated that CHFR 
staining was inversely correlated with tumor size.  In view of this evidence that CHFR 
may have tumor suppressive properties, we mimicked cellular loss of expression via 
stable shRNA and transient siRNA targeting CHFR in two IHMEC lines.  This decrease 
in expression led to the acquisition of many phenotypes associated with malignant 
progression.   
Materials and Methods 
Cell Culture 
MCF10A and Hs578T cell lines were obtained from the American Type Culture 
Collection (AATC) and grown under recommended conditions.  The human papilloma 
virus (HPV)-immortalized non-tumorigenic mammary cell line, HPV4-12, was developed 
and provided by S.P. Ethier  (now available from Asterand) and cultured according to 
specified conditions [73].  A detailed description of relevant cell line information, 
including origins and hormone receptor status, has been compiled by Neve, R.M. et al 
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[74].  Table 3.1 briefly describes the three cell lines predominantly used in these 
experiments.  
For retroviral transduction, PT67 packaging cells were transfected using FuGENE 
6 with 10.0 μg of pRNA-H1.1/Hygro vector (GenScript Corp.) containing either a 
scrambled sequence or a CHFR shRNA construct targeting nucleotides 324-344, 1491-
1511, or 2497-2517  (accession no. AF170724).  We used the pLPCX retroviral vector 
for overexpression of full-length CHFR in Hs578T cells (Clontech Laboratories).  Virus 
was collected after 48 hours and purified with a 0.45-micron filter.  Equal parts of 
retrovirus-containing media and normal growth media were added to 1x106 cells.  Fresh 
media was added 24 hours later and selection with 20.0 μg/ml hygromycin (pRNAH1.1) 
or 1.5 μg/ml puromycin (pLPCX) began 48 hours post-infection.  The resulting 
polyclonal cell population stably expressing the CHFR construct(s) was subsequently 
used for experimentation.  MCF10A cells were transduced with all three shRNA 
constructs whereas HPV4-12 cells were transduced with the shRNA construct targeting 
nucleotides 324-344 to achieve maximum knockdown.   
Transient transfection of siControl or a pool of four siRNAs targeting CHFR 
(siGENOME, Dharmacon RNA Technologies) was performed according to 
manufacturer’s instructions.  HPV4-12 cells were transfected using Dharmafect2 
lipofection reagent and MCF10A cells with Dharmafect1.  For both methods, stable 
shRNA and transient siRNA, knockdown of CHFR expression was confirmed using 
























To assess CHFR protein levels in asynchronous cells, 60.0 μg of total protein 
from 70-80% confluent cell cultures was separated on 10% SDS-PAGE gels using the 
Criterion or Ready gel systems (Bio-Rad Laboratories) and immunoblotted to Hybond-P 
PVDF membrane (Amersham Biosciences).  Following one hour of incubation in a 
blocking solution of 2.5% non-fat dry milk and 0.1% TBS-Tween20, a monoclonal 
antibody against CHFR (Abnova Corp.) used at a 1:500 dilution in 2.5% non-fat dry milk 
and 0.05% TBS-Tween20 and incubated overnight at 4°C.  CHFR was detected by 
hybridization with a goat anti-mouse:HRP secondary antibody (Cell Signaling 
Technology) at a 1:2000 dilution in 2.5% non-fat dry milk and 0.05% TBS-Tween20.  
For a loading control, blots were blocked in 5% non-fat dry milk and 0.1% TBS-
Tween20 for one hour.  The blots were then stripped and immunoblotted again with an 
antibody against GAPDH as a control.  The anti-GAPDH antibody (Abcam) was used at 
a 1:10000 dilution and detected with a goat anti-mouse:HRP antibody at a 1:5,000 
dilution, both in 5% non-fat dry milk and 0.05% TBS-Tween20.  The Super Signal West 
Pico Chemiluminescent kit (Pierce) was used for detection and blots were exposed to 
Kodak Biomax XAR film.  Relative CHFR expression was assessed by densitometry 
with the IS-1000 Digital Imaging System (Alpha Innotech Corp.).  A ratio of 
CHFR:GAPDH was calculated and normalized to the control samples.  
 
RT-PCR  
For duplex RT-PCR, reaction conditions were optimized as previously described 
[75].  Primer concentrations were optimized to create equal band intensities between 
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CHFR and the internal GAPDH loading control, and the cycle number that resulted in the 
logarithmic phase of product generation was determined.  Total RNA was isolated via the 
Qiagen RNeasy RNA isolation kit.  cDNA was then generated from 1.0 μg of total RNA 
using the Qiagen Omniscipt Reverse Transcription kit and random hexamer primers.  
Primers to amplify CHFR cDNA were (forward/reverse, 5’-3’):  
CAGCAGTCCAGGATTACGTGTG/AGCAGTCAGGACGGGATGTTAC (500 bp) or 
TCCCCAGCAATAAACTGGTC/GTATGCCACGTTGTGTTCCG (205 bp) and primers 
for GAPDH cDNA amplification were (forward/reverse, 5’-3’): 
AGTCCATGCCATCACTGCCA/GGTGTCGCTGTTGAAGTCAG (340 bp).  PCR 
products were separated on a 1.0% ethidium bromide-stained agarose gel.  Densitometry 
was performed using the IS-1000 Digital Imaging System (Alpha Innotech Corp.) 
For quantitative RT-PCR, cDNA samples from IHMECs and breast cancer cell 
lines were amplified in triplicate from the same total RNA sample following the 
manufacturer’s instructions.  Samples were amplified using TaqMan MGB FAM dye-
labeled in an ABI7900HT model Real-Time PCR machine (Applied Biosystems).  To 
amplify CHFR cDNA, probe set Hs00217191_m1 was utilized while the control, 
GAPDH, was amplified with probe set Hs99999905_m1 (Applied Biosystems).  
 
Growth Curve Analysis 
 To determine the growth rate, 4x104 cells were plated into each well in 6-well 
plates.  Cells from three different wells were then manually counted with a 
hemacytometer.  A new set of three wells were counted every two to three days for seven 
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or nine days, at which point at least one cell line began to reach confluence.  Average cell 
numbers from the three wells were then plotted as a function of a time.   
 
Immunofluorescence and Mitotic Index 
 Early mitotic chromosomes were identified via immunofluorescence using a 
Histone H3-phospho-Ser28 antibody (Upstate) at a 1:100 dilution and anti-rabbit 
Alexafluor488 secondary antibody at a 1:500 dilution both diluted in blocking solution.  
Cells were blocked in 5% non-fat dry milk, 1% BSA, and 0.025% TritonX-100 solution 
in PBS for one hour prior to incubation with primary antibody.  Cells were counterstained 
with phalloidin conjugated to Alexafluor568 to detect the actin cytoskeleton and ProLong 
Gold anti-fade reagent with DAPI to detect all nuclei (both available from Molecular 
Probes/Invitrogen).  Cells were visualized using a compound Leica DMRB miscroscope 
with a Leitz laser at 63x magnification (W. Nuhsbaum).  The mitotic index was the 
percentage of H3-Ser28 stained nuclei from 1000 total (DAPI-stained) nuclei. 
To assess for vimentin staining, cells were plated 24 hours prior to staining at a 
density of 3x104 cells per chamber in two-chambered slides.  MCF10A cells that were 
transiently transfected with a pool of four CHFR siRNAs were transfected 48 hours prior 
to seeding for immunofluorescence.  Cells were blocked in 5% non-fat dry milk, 1% 
BSA, and 0.025% TritonX-100 solution in PBS for one hour prior to incubation with 
primary antibody.  Staining was performed using an anti-vimentin antibody (1:40, Sigma 
Aldrich) which was hybridized in blocking buffer overnight at 4°C, and detected with an 
anti-mouse:Alexafluor 594 secondary antibody in blocking buffer for one hour at room 
temperature.  Cells were counterstained with phalloidin:Alexafluor488, and preserved in 
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ProLong Gold antifade reagent with DAPI  (all from Molecular Probes/Invitrogen, 
Carlsbad, CA).  Cells were visualized using a compound Leica DMRB miscroscope with 
a Leitz laser at 63x magnification (W. Nuhsbaum, Inc.) and an Optronics camera system.   
 
Apoptosis Assay/Annexin V Detection 
 Cells were seeded at 3x105 cells per well in 6-well plates and transiently 
transfected with CHFR siRNA or the siControl negative control as described previously.  
Fifty-two hours post-transfection, cells were treated with either 0.67 μM nocodazole or 
1.0 μM paclitaxel for 20 hours (both Sigma-Aldrich).  Cells were then collected and 
labeled for Annexin V on the cell surface and DNA was stained with propidium iodide 
using the Vybrant Apoptosis Assay kit 2 according to manufacture’s instructions 
(Molecular Probes/Invitrogen).  Cells were then analyzed by flow cytometry and the 
apoptotic cells were those that stained for Annexin V on the cell surface but were 
negative for propidium iodide staining.  The graphs presented indicate the percentage of 
apoptotic cells as assessed by flow cytometry.   
 
Matrigel Invasion Assay 
 This invasion assay was performed according to manufacturer’s instructions (BD 
Biosciences).  In short, 2.5x104 cells suspended in media without chemoattractant were 
plated in triplicate in Matrigel baskets in a 24-well plate.  In the chamber below the 
baskets, either media without chemoattractant as a negative control or media containing 
chemoattractant was added.  Chemoattractants for each cell line were:  (1) HPV4-12 
cells: 5% FBS, 1.0 μg/ml hydrocortisone, 10.0 μg/ml insulin, 100.0 ng/ml cholera toxin, 
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and 10.0 ng/ml epidermal growth factor, (2) MCF10A cells:  10% horse serum, 0.5 μg/ml 
hydrocortisone, 100.0 ng/ml cholera toxin, 10.0 μg/ml insulin, and 20.0 ng/ml epidermal 
growth factor, and (3) Hs578T cells: 10% FBS and 10.0 μg/ml insulin. 
Cells were incubated for 22 hours at 37°C in 5% CO2 for MCF10A and Hs578T 
cells or 10% CO2 for HPV4-12 cells.  The interior of the chambers were cleaned and the 
cells on the exterior were fixed and stained using the PROTOCOL Hema 3 staining kit 
(Fisher Scientific Co.).  The number of stained cells on the exterior were counted using a 
Nikon TMS inverted microscope at 10x magnification.     
 
Scrape Motility Assay 
Cells were grown to confluency in 6-well plates and the cell monolayer was 
mechanically scarred using a plastic pipette tip.  Cells were visualized for movement into 
the scratched surface with a Leica DMIRB inverted microscope with phase contrast 
optics and a 10x objective lens.  Images were captured with a SPOT camera system 
(Diagnostic Instruments Inc.).  The motility phenotype was quantified by using the 
ImageQuant v5.2 software package (GE Healthcare/Amersham Biosciences) to determine 
the area of the initial scrape and then the area of the same wound 24 hours later.  Data are 
presented as the percentage of the scraped area that remains after the end-point.     
 
Cellular Morphology 
 Cellular morphology was recorded when cultured cells reached 100% confluence.  
Images were gathered using a Leica DMIL inverted microscope (W. Nuhsbaum, Inc.) at 
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10x magnification and a SPOT RT Color camera with SPOT Advanced digital imaging 
software (Diagnostic Instruments Inc.).          
 
Soft Agar Assay for Colony Formation 
 To perform the soft agar assay, an underlayer of a 1:1 mixture of 1.2% Noble agar 
and cell line-appropriate growth media with 40% serum was added to 6-well plates and 
allowed to solidify at room temperature for approximately 15 minutes.  To create the 
overlayer for each well, we combined 2.0 ml of growth media with 40% serum, 1.0ml of 
1.2% Noble agar, 0.6ml water, and 1.0x104 cells and added it on top of the solidified 
underlayer.  The solution solidified at room temperature for 15 minutes.  Cells were 
maintained at 37°C in a humidified incubator with the appropriate levels of CO2 and two 
to three drops of media were added to each well every three days.  After 30 days, the 
number of colonies present in the overlayer was counted manually. 
 
Ploidy Status and Nucleolar Changes 
 Cells were collected at 70% confluence by trypsinization and resuspended in 
0.075 M KCl on ice for 30 minutes.  Cells were fixed in a 3:1 mixture of methanol and 
glacial acetic acid with mild vortexing, dropped onto glass slides, and stained with 544 
μg/ml Giemsa solution.  To determine ploidy, the number of chromosomes was counted 
in at least 25 metaphases for each cell line and its derivatives.  
 To assess nucleolar changes, cells were prepared as described above and the 
number of nucleoli was counted in at least 50 cells, in triplicate, for each cell line.  For 
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both methods listed here, images were recorded with a compound Leitz DMRB 
miscroscope (W. Nuhsbaum, Inc.) at 40x magnification and an Optronics camera.  
 
Statistical Analysis 
 The ANOVA test was used to determine statistical significance when comparing 
quantitative phenotypic differences.  Student’s t-test was used to confirm a lack of 
statistical significance between parental and negative control cells for each experiment.  
For all tests, statistical significance was defined as p≤0.05.  Error bars in the graphs 
presented here represent the standard error of the mean (SEM).       
Results 
Stable Loss of CHFR Results in Increased Growth Rates and Impairs the 
Checkpoint 
 CHFR expression was significantly decreased using a stably expressed shRNA 
construct, as determined by Western blotting and semi-quantitative duplex RT-PCR, in 
two IHMEC lines: HPV4-12 and MCF10A (Figure 3.1).  Stable expression of shRNA 
reduced the amount of CHFR protein by at least 60% in HPV4-12 cells and by nearly 
80% in MCF10A cells, and reduced the amount of mRNA by about 70% as determined 
by densitometry. 
We first noticed that when CHFR expression was decreased by shRNA, the 
population growth rate dramatically increased for both IHMECs by at least three-fold 
over the course of 7-9 days (p≤0.03 for MCF10A and p≤0.001 for HPV4-12; Figure 3.2).  
The difference in growth rates is consistent over the time course but is most dramatic in 
61 
 
the last few days, possibly due to a cumulative effect, or because the cells grow slowly 
when seeded at a low density and grow better when the culture is denser.   
In order to understand this increase in population growth, we assessed the 
percentage of mitotic cells by using immunofluorescence to stain cells for the mitotic 
marker phosphorylated histone H3-Ser28 – a residue that is phosphorylated during 
metaphase and is gradually dephosphorylated in anaphase and is associated with the 
initiation of chromosome condensation [88].  CHFR has been shown to delay 
chromosome condensation as part of the checkpoint response [17].  Therefore, phospho-
H3-Ser28 as a marker of condensed chromosomes is a good method to determine if the 
cells have passed through the CHFR checkpoint and entered the later stages of mitosis.  
This method was also used to determine mitotic index, which was calculated as the 
percentage of phospho-H3-Ser28 positive cells in the population.  There was a 
statistically significant five-to-six-fold increase in the number of H3-Ser28 stained 
(mitotic) cells in the population when CHFR expression was lowered by shRNA in both 
cell lines.  This showed that more cells went through the CHFR checkpoint, entering the 
later stages of mitosis, with or without the stress of microtubule poisons such as 
nocodazole (p<0.05, Figure 3.3).  In addition, the increase in phospho-H3-Ser28 positive 
cells following nocodazole treatment indicated that the checkpoint response to 
microtubule stress was bypassed when CHFR expression was decreased by shRNA 
(Figure 3.4).  Though no difference was observed in MCF10A cells transiently 
transfected with CHFR siRNA, a similar increase in H3-Ser28 phosphorylation was 





Figure 3.1: Targeting CHFR by RNAi dramatically decreases mRNA and protein 
expression. 
 
Top: Western blotting shows a dramatic loss of CHFR protein following stable shRNA 
expression by retroviral transduction and transient siRNA transfection.  HPV4-12 with 
CHFR shRNA3 had at least a 60% decrease while MCF10A with CHFRshRNA123 
showed nearly an 80% stable knockdown of CHFR expression compared to parental and 
scrambled shRNA controls.  Transient siRNA transfection resulted in a 95% decrease in 
HPV4-12 cells and an approximately 99% decrease in CHFR protein in MCF10A cells 
72 hours after transfection.  Bottom:  Semi-quantitative duplex RT-PCR indicates a 





Figure 3.2: Stably decreased CHFR expression causes increased growth rates. 
 
Growth curves for (A) HPV4-12 cells (top) and (B) MCF10A cells (bottom) following 
stable shRNA expression against CHFR (▲) compared to the parental cell lines (♦) and 
the scrambled shRNA (■) negative control cell lines.  Cells were counted in triplicate 
every two days until at least one line reached confluency.  The graph represents the 
average number of cells counted on each day per cell line.  Cells with decreased CHFR 
expression by shRNA had a faster growth rate compared to the parental and scrambled 








Figure 3.3:  Decreased CHFR expression causes an increase in the mitotic index. 
The mitotic index of cells with or without CHFR shRNA is represented as the average 
percentage of histone H3-Ser28 stained nuclei, which is a marker of early metaphase 
cells, out of ≥1000 total (DAPI-stained) nuclei from triplicate experiments for each cell 
line.  Cells were either not treated with nocodazole in order to determine the basal 
percentage of mitotic cells in the population.  Cells with decreased CHFR expression by 
shRNA showed approximately a six-fold increase in mitotic cells when compared to the 





Figure 3.4:  CHFR shRNA impaired the nocodazole-induced early mitotic 
checkpoint. 
 
The mitotic index of cells is represented as the average percentage of histone H3-
Ser28 stained nuclei out of ≥1000 total (DAPI-stained) nuclei from triplicate experiments 
for each cell line.  Cells were treated with 200 ng/ml nocodazole to test for checkpoint 
response.  (Top) Cells transduced with CHFR shRNA showed a four- or ten-fold increase 
in mitotic cells after nocodazole treatment when compared to the parental and scrambled 
shRNA controls.  (Bottom) A similar trend was found in HPV4-12 cells transiently 
transfected with CHFR siRNA (p<0.07) but no change was observed in MCF10A cells 




for 72 hours prior to staining to decrease CHFR protein by approximately 95% (p<0.07, 
Figure 3.1 and 3.4). 
To determine if decreasing CHFR expression would alter the apoptotic response 
of the cells, we tested untreated or nocodazole-treated cells for the presence of Annexin 
V on the cell surface by flow cytometry and used propidium iodide staining to 
differentiate between apoptotic and necrotic cells [89].  We found no difference between 
the cell lines with and without CHFR when they were untreated, which suggested that the 
increase in growth rates observed in the cells was not due to a decrease in cell death.  In 
addition, there was no statistically significant difference in HPV4-12 cells transiently 
transfected with CHFR siRNA when compared to the mock transfected and siControl 
transfected cells following treatment with nocodazole.  However, when CHFR expression 
was transiently decreased in MCF10A cells, there was a three-fold increase in apoptotic 
cells following nocodazole treatment (p<0.05, Figure 3.5).  
 
The Stable Loss of CHFR Leads to Enhanced Invasive Potential and Increased 
Motility 
To determine if decreasing CHFR expression would cause phenotypic changes 
reminiscent of cellular transformation, IHMECs with or without CHFR shRNA were 
subjected to the Matrigel invasion assay and the scrape (wound) motility assay.  
Surprisingly, there was a dramatic increase in the ability of the cells to invade through the 
Matrigel collagen matrix when CHFR expression was low: a 23-fold increase for 







Figure 3.5: Transient knockdown of CHFR expression by siRNA increased the 
apoptotic response to nocodazole. 
 
Transiently decreasing CHFR by siRNA in MCF10A cells, but not HPV4-12 cells, 
resulted in an increased apoptotic response to nocodazole.  An Annexin V antibody was 
used to detect the presence of Annexin V on the cell surface.  Cells were counterstained 
with propidium iodide and assessed by flow cytometry.  The percent of Annexin V-
positive and propidium iodide-negative (apoptotic) cells are presented in the graph.  Two 








     
 
Figure 3.6: Stable loss of CHFR expression by shRNA caused enhanced invasion 
through Matrigel. 
 
Stable knockdown of CHFR expression by shRNA resulted in greatly increased invasive 
potential through a Matrigel collagen matrix for both (A) HPV4-12 cells (top) and (B) 
MCF10A cells (bottom) compared to the control cell lines (parental and scrambled 







This dramatic change was also observed after transient transfection with a pool of four 
siRNAs, each targeting a different locus in CHFR, which indicated that this phenotype is 
directly caused by CHFR loss and is not a result of clonal selection during culture of the 
stable shRNA lines (Figures 3.1 and 3.7).   
To assess changes in cellular motility, a wound was created in a confluent culture 
of IHMEC cells with or without CHFR shRNA.  Motility was described as the percentage 
of the area of the initial wound that remained after a recovery period.  IHMEC lines are 
not readily motile when their growth surface has been damaged and the remnants of the 
initial wound are clearly visible days later.  However, when CHFR expression was 
decreased by stable shRNA, the cells became so motile that the wound was nearly 
entirely closed 24 (Figure 3.8).  This was not a function of the increased population 
growth rates as cells with filipodia were clearly seen in the center of the wound less than 
24 hours later.  In addition, the assay was completed prior to the population doubling 
time as indicated in the growth curves presented in Figure 3.2. 
 
Stably Decreased Levels of CHFR Causes Morphological Changes and Induces 
Colony Formation in Soft Agar 
Normally, cells contain only one or two nucleoli in a nucleus and one frequently 
characterized change in cancer cells is increased number of nucleoli.  In fact, changes in 
the number of nucleoli (>3) is strongly correlated with a negative prognosis for survival 
in breast cancer patients [90].  Interestingly, both IHMEC cell lines exhibited a marked 
increase in the number of nucleoli present in the nucleus, which was defined as three or 
more nucleoli, when CHFR expression was knocked down by shRNA.  We found that 
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Figure 3.7: Transient loss of CHFR expression by siRNA caused enhanced cellular 
invasion through Matrigel. 
 
Transient knockdown of CHFR expression results in greatly increased invasive potential 
through a Matrigel collagen matrix for both (A) HPV4-12 cells and (B) MCF10A cells 
compared to the control cell lines (mock transfected and siControl).  Cells were 
transfected with siRNA and 48 hours later were seeded for the invasion assay, which was 
completed after 24 hours such that the assay was completed when CHFR expression was 






Figure 3.8: Loss of CHFR expression by stable shRNA increases cellular motility. 
 
(A) Graphical representation of the degree of wound closure.  Motility is 
described as the percentage of the original wounded area that remains vacant after 
incubation.  The area of the vacant surface was calculated using ImageQuant v5.2 
software.  Two asterisks (**) indicates p≤0.001 and one asterisk (*) indicates p≤0.05 by 
ANOVA testing.  (B) Digital phase contrast images at 10x magnification showing an 
increase in motility (closing a scraped wound in confluent culture) for HPV-12 (left) and 
MCF10A (right) cells following stable CHFR shRNA expression compared to controls.  








29% of MCF10A:CHFRshRNA cells (compared to 9% for controls, p≤0.001) and 23% of 
HPV4-12:CHFRshRNA cells had greater than three nucleoli (compared to 13% for 
controls p≤0.08; Figure 3.9).  This change in nucleolar organization and number may 
indicate alterations in cellular metabolism related to proliferation, genome organization, 
or gene expression.         
Further evidence for the acquisition of tumorigenic phenotypes following 
knockdown of CHFR expression was noticed only in MCF10A cells.  We observed that 
MCF10A cells with CHFR shRNA underwent a morphological change following 
approximately 10 passages in culture.  These cells became elongated and showed more 
variability in cell size, which is suggestive of the epithelial-to-mesenchymal transition 
that is often observed during tumorigenesis (Figure 3.10).  Further confirmation of this 
transition was indicated by increased expression of Vimentin, a marker of mesenchymal 
cells, as shown by immunofluorescence (Figure 3.11).  To determine if the loss of CHFR 
altered the tumorigenicity of these cell lines, parental, scrambled shRNA, and CHFR 
shRNA-expressing cells were suspended in a mix of soft agar and growth media and 
assessed for their ability to form colonies.  The MCF10A cell line has already been 
characterized as being tumorigenic in soft agar and the loss of CHFR did not enhance this 
phenotype.  However, the HPV4-12 cell line does not form colonies in soft agar but when 
CHFR expression was decreased by shRNA, there was a modest but very significant 
increase in the number of colonies formed in soft agar (p<0.001, Figure 3.12), indicating 





       
 
Figure 3.9: MCF10A cells with decreased CHFR expression by shRNA have 
amplified numbers of nucleoli. 
 
(A) In Giemsa-stained cells, the nucleolus is depicted as a dark spot within the nucleus.  
Parental (far left) and scrambled shRNA controls (middle) normally contain one or two 
nucleoli whereas CHFR shRNA cells more frequently had greater than three nucleoli 
(arrows).  (B) Graphical representation of the percentage of cells with greater than three 













Figure 3.10:  Stably decreased CHFR expression in MCF10A cells results in altered 
cellular morphology resembling an epithelial-to-mesenchymal transition. 
 
MCF10A cells visualized by phase contrast light microscopy show a change in cellular 
shape from epithelial to an elongated morphology reminiscent of an epithelial to 









    
 
 
Figure 3.11:  Increased Vimentin staining in cells with decreased CHFR expression 
by RNAi indicated an epithelial-to-mesenchymal transition. 
 
(A) MCF10A cells stably transduced with CHFR shRNA123 or the non-targeting 
scrambled shRNA construct.  (B)  MCF10A mock transfected, siControl negative control 
transfected, and cells transiently transfected with a pool of CHFR siRNA.  Cells were 
stained by immunofluorescence for DNA (DAPI, blue), F-actin (green), and Vimentin 
(red) and images were merged (far right panel).  Increased Vimentin expression indicates 








Figure 3.12: Stable loss of CHFR expression by shRNA in HPV4-12 cells causes 
amplified colony formation in soft agar, suggesting cellular transformation. 
 
The graph depicts the three-fold increase in colonies formed by HPV4-12 cells when 
CHFR expression is decreased.  Ten thousand cells were suspended in a mixture of noble 












Over-expression of CHFR Reverses Tumorigenic Phenotypes in Breast Cancer Cells 
We next determined if CHFR over-expression would affect a tumorigenic breast 
cancer cell line, Hs578T, which has no endogenous expression of CHFR protein.  
Hs578T cells over-expressed CHFR through a stably transduced retroviral construct 
containing the full-length cDNA (Figure 3.13).  Over-expressing CHFR in Hs578T cells 
did not alter their apoptotic response to nocodazole or decrease colony formation in soft 
agar (data not shown).  However, CHFR over-expression rescued other tumorigenic 
phenotypes, making the cells act less like cancer cells.  Importantly, their ability to 
invade through a Matrigel collagen matrix dramatically decreased by 25-fold (p≤0.001; 
Figure 3.14) and there was nearly a six-fold decrease in motility using the scrape assay 
(p≤0.001; Figure 3.15, quantified in the right panel).  Over-expression of CHFR resulted 
in a significant decrease in growth rates (p<0.05, Figure 3.16 left panel) and fewer 
mitotic cells, as indicated by positive phospho-histone H3-Ser28 staining (p<0.05, Figure 
3.17).  The prophase checkpoint also was partially restored in Hs578T cells over-
expressing CHFR (p<0.05, Figure 3.17). 
 
Stable Knockdown of CHFR Expression Leads to Genomic Instability 
 Since genomic instability was previously reported for Chfr null mouse embryonic 
fibroblasts, we assessed the ploidy status of IHMECs after stable CHFR shRNA 
expression.  Strikingly, 60-70% of these cells showed increased aneuploidy with 
anywhere from 49 to over 85 chromosomes, as opposed to less than 5% of cells in the 








Figure 3.13: CHFR was stably over-expressed in the Hs578T breast cancer cell line 
by retroviral transduction. 
Western blot showing increased CHFR expression (top) in cells retrovirally transduced 
with a Flag-tagged CHFR construct compared to the parental and empty vector negative 










Figure 3.14: Over-expression of CHFR in the Hs578T breast cancer cell line 
dramatically decreased the cells’ invasive potential through Matrigel. 
 
Over-expression of CHFR in Hs578T cancer cells results in 25-fold loss of invasive 
potential through a Matrigel collagen matrix.  Cells were seeded in the upper chamber of 







Figure 3.15: Over-expression of CHFR in Hs578T breast cancer cells decreased 
cellular motility. 
 
(A) Phase contrast images at 10x magnification showing an increase in motility for 
Hs578T cells following stable CHFR over-expression.  The “0 hrs” images depict the 
initial wound in the culture and the “24 hrs” images show wound closure after 24 hours.  
Hs578T cells over-expressing CHFR were less motile than their control counterparts 
were and could not sufficiently close the wound in less than 24 hours.  (B) Graphical 
representation of the degree of wound closure depicted on the left; the graph describes the 
percentage of the original scraped area remaining after incubation for each cell line.  Two 












Figure 3.16: Stable over-expression of CHFR in Hs578T cells causes increased 
growth rates. 
 
Growth curve analysis over the span of nine days showed that Hs578T breast cancer cells 
overexpressing CHFR (▲) had a slower growth rate, as indicated by a lower average cell 
count, than the parental (♦) or the vector negative control (■), despite being seeded at 









Figure 3.17:  Hs578T cells over-expressing CHFR have a lower mitotic index and a 
partially restored early mitotic checkpoint. 
 
Immunofluorescence staining for phospho-histone H3-Ser28 was used as a marker for 
mitotic cells.  The percentage of cells positive for p-H3-Ser28 staining out of at least 
1000 total nuclei (DAPI-stained) is presented for each cell line.  Over-expression of 
CHFR led to approximately 50% fewer mitotic cells compared to parental and empty 
vector controls in both untreated and nocodazole (200 ng/ml) treated cells, indicating at 
least a partially restored checkpoint and a decrease in proliferation in untreated cells.  
One asterisk (*) indicates p<0.05. 
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Figure 3.18: Stable loss of CHFR expression by shRNA in IHMECs leads to 
increased aneuploidy. 
 
(A) Giemsa-stained metaphase spreads of parental, negative control, and CHFR shRNA 
cells.  IHMECs with lowered CHFR expression showed a greatly increased incidence of 
aneuploidy.  Both IHMEC cell lines are hyperdiploid and normally have either 48 
chromosomes (MCF10A) or 49 chromosomes (HPV4-12).  (B) Quantification of 
increased aneuploidy in CHFR shRNA cells showing that low CHFR expression results 
in 55-72% of the cells in the population becoming more aneuploid.  The graph represents 
the percent of cells with increased aneuploidy above the normal hyperdiploid state, from 
25 counted metaphases per trial, for each cell line.  Two asterisks (**) denotes p≤0.001 as 





The findings presented here contribute significantly to the characterization of 
CHFR as a cancer-relevant gene with tumor suppressive properties.  This work provided 
evidence that decreasing CHFR mRNA and protein using shRNA/siRNA resulted in two 
IHMEC cell lines acquiring phenotypes associated with malignant progression.  These 
phenotypes included increased growth rates and mitotic indexes, the cells acquired the 
abilities of invasion and motility, and a striking percentage of cells became more 
aneuploid.  In addition, the HPV4-12 cells without CHFR were able to form colonies in 
soft agar, an indication of cellular transformation, and the MCF10A cells without CHFR 
became sensitive to microtubule poisons and underwent an epithelial-to-mesenchymal 
morphology change.  When CHFR was over-expressed in Hs578T breast cancer cells, the 
data suggested that higher CHFR levels did not have any adverse consequences and, in 
fact, reversed some tumorigenic phenotypes thereby further supporting the role of CHFR 
as a tumor suppressor.  When the CHFR expression data is combined with the results of 
the phenotypic analysis in vitro and the correlation with tumor size in vivo, it appears that 
the loss of CHFR is relevant to tumorigenesis in mammary epithelial cells.   
Importantly, decreased CHFR expression led to an increase in the number of 
mitotic (metaphase and anaphase) cells in the population.  Previously, this phenotype had 
only been described to occur in the presence of nocodazole and was thought to be due to 
an impaired checkpoint.  However, the fact that this phenomenon also occurs without 
microtubule poisons suggests that CHFR can possibly play a wider role in regulating the 
timing of mitotic entry.  This may help explain why the growth rates were faster in cells 
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stably expressing CHFR shRNA and may be one contributing factor as to why CHFR-
negative tumors tended to be larger. 
 Two of the most striking changes that resulted from altering CHFR expression 
were changes in invasion and motility of cells in vitro.  This is the first time that CHFR 
has been implicated in a functional role other than cell-cycle regulation.  Considering its 
proposed role of monitoring microtubule dynamics as indicated by its initiation of the 
checkpoint in response to microtubule stress, it is hypothesized that CHFR has an even 
larger part in cytoskeletal organization in which loss would more easily allow for the 
necessary reorganization of the cytoskeletal network required for motility.  In addition, if 
the phenotypes observed in culture are found to mirror those seen in cancer patients (ie: 
patients with low CHFR tumors have a higher incidence of distant metastases), then 
CHFR expression may be an indicator for tumor stage and/or patient prognosis. 
 Our report that low CHFR expression leads to genomic instability corroborates 
previously published work in the mouse.  These data are suggestive of a problem with the 
structure or function of the mitotic spindle that is not corrected due to an impaired CHFR 
checkpoint.  However it could also indicate a defect in cytokinesis, which is plausible 
since work with the two yeast orthologs of CHFR show an interaction with the septin 
cytoskeletal network and the orthologs were shown to function in both the spindle 
checkpoint and in cytokinesis [10, 11].  Given the relatively frequent occurrence of 
low/lost CHFR in many types of tumors, this work may begin to explain the conundrum 
of the prevalence of aneuploidy in cancers but the lack of defective spindle checkpoint 
mediators such as the MAD and BUB proteins. 
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 It is not surprising that the same phenotypes were not always observed in the two 
cell lines tested.  This is likely due to the unique genetic defects that caused the 
immortalization of the cell lines, thereby providing a clue to the genetic and physical 
interactions that CHFR has within the cell.  Specifically, the HPV4-12 cell line was 
immortalized with the HPV E6/E7 protein to inhibit p53 and pRb function while the 
MCF10A line was spontaneously immortalized following a t(3;9)(p14;p21) translocation 
that disrupted the p15/p16 gene in addition to other chromosomal rearrangements [91, 
92].  The genetic differences may help to explain why MCF10A cells undergo a 
morphological change and an increase in apoptosis in response to microtubule poisons 
after CHFR shRNA, whereas HPV4-12 cells do not.  Differences may also be attributed 
to the fact that these two IHMEC lines are grown in different media with different levels 
of CO2, but it should be noted that the media are very similar and contain nearly identical 
supplements.   
This work on the phenotypic changes that arise in vitro with CHFR expression 
variation provides a unique insight as to what may happen in cancer patients and presents 
many new avenues through which to study CHFR expression, function, and molecular 
interactions.  We also comprehensively characterize the phenotypic changes that 
resemble cellular transformation in normal IHMEC cells when CHFR expression is 
substantially reduced.  Through the combined findings of this work, we find the loss of 
CHFR to be an interesting dichotomy in breast cancer.  This report shows that, on one 
hand, the loss of CHFR expression may indicate a larger and more aggressive tumor 
whereas in a surprising beneficial twist, it also makes the cancer cells sensitive to 
traditional chemotherapeutic agents that target the microtubules.  It seems that as 
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evidence builds, CHFR will have potent tumor suppressive functions in breast cancer and 
may be a biomarker for tumor sensitivity to taxane treatment. 
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LOSS OF CHFR CAUSES GENOMIC INSTABILITY BY DISRUPTING 
MITOTIC SPINDLE PROTEINS 
 
Summary 
To investigate CHFR’s role in breast cancer, we decreased CHFR expression by 
siRNA in MCF10A cells.  This resulted in increased aneuploidy caused by mitotic 
defects including misaligned metaphase chromosomes, lagging anaphase chromosomes, 
multi-polar mitotic spindles, and multi-nucleated cells.  CHFR siRNA also increased 
Aurora A expression and caused MAD2 and BUBR1 mislocalization during mitosis, 
suggesting that CHFR is involved in the mitotic spindle checkpoint and genomic 
instability.  Furthermore, we found that CHFR interacted with both Aurora A and MAD2.  
These findings, along with CHFR’s reported role in responding to microtubule poisons, 
suggested that CHFR might also interact with tubulins.  We discovered that CHFR 
interacted with, and ubiquitinated, α-tubulin, and CHFR siRNA increased expression of 
both unmodified and acetylated α-tubulin.  Importantly, our results suggest a novel role 
for CHFR regulating chromosome segregation where decreased expression, as seen in 






As previously noted, Checkpoint with FHA and RING Finger (CHFR) is 
recognized as a novel mitotic stress checkpoint pathway regulator and biomarker for 
treatment response to taxanes.  It delays cells in prophase, prior to the mitotic spindle 
checkpoint, after microtubule poison  exposure (i.e. nocodazole or paclitaxel) [3, 7, 18-
20, 58, 63].  Subsequently, CHFR has been implicated in oncogenesis.  CHFR expression 
is lost or decreased in tumors compared to normal tissues, sometimes due to promoter 
hyper-methylation [19, 21, 33, 44, 49, 55, 59, 63]. Importantly, CHFR has tumor 
suppressive activity in both a knockout mouse model [8] and in immortalized human 
mammary epithelial cells (IHMECs) [20].  Long-term loss of CHFR expression led to 
abnormal chromosome complements (i.e. increased aneuploidy) in both models.   
Aneuploidy is a hallmark of many cancers.  It may result from diverse mitotic 
defects including multi-polar spindles secondary to aberrant cytokinesis or centrosome 
amplification, sister chromatid cohesion defects, incorrect centromere attachment, or an 
impaired mitotic spindle assembly checkpoint (“spindle checkpoint”) [93].  The spindle 
checkpoint prevents chromosome mis-segregation during cell division by delaying 
anaphase until the kinetochores of all sister chromatids are attached to the mitotic spindle.  
Spindle checkpoint gene mutations are rare, especially in breast cancers, but many cancer 
cells have an impaired or unregulated spindle checkpoint [93-95].   
  Aurora A kinase is crucial for centrosome amplification and maturation, mitotic 
entry, and spindle assembly [96-98]. Aurora A over-expression can override the spindle 
checkpoint, resulting in mitotic defects and mislocalization of the key spindle checkpoint 
proteins BUBR1 and MAD2, among others [99, 100].  Aurora A is amplified and/or 
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overexpressed in many cancers and correlates with improved patient survival following 
treatment with microtubule-targeting taxanes [101, 102].  Importantly, Aurora A may be 
a target for CHFR-mediated ubiquitination and subsequent proteasome degradation [8].  
This suggests that CHFR expression may be important for genome stability and cellular 
responses to taxanes, potentially through its regulation of Aurora A expression.   
It was hypothesized that the transient loss of CHFR causes genomic instability 
due to defects in mitotic spindle formation and function, potentially through Aurora A 
overexpression.  To test this, CHFR expression was transiently decreased by siRNA in 
the genomically stable IHMEC cell line, MCF10A.  Subsequent analysis of these cells 
revealed they became more aneuploid compared to the parental cells, had four major 
mitotic defects, showed mislocalization of the key spindle checkpoint proteins BUBR1 
and MAD2, and had increased expression of mitotic proteins including Aurora A, α-
tubulin, and acetylated α-tubulin.   
Materials and Methods 
Cell Culture 
MCF10A and HEK293 cells were obtained from the American Type Culture 
Collection and cultured under recommended conditions.  For CHFR knockdown, cells 
were untransfected (“mock”) or transfected with 2.0 μM of either a non-targeting 
siControl siRNA or siRNAs targeting CHFR using Dharmafect1 according to 
manufacturer’s instructions and analyzed 72 hours later (siGENOME, Dharmacon RNA 
Technologies).  Cells were transfected with 6.0 μg of a Flag-tagged Aurora A construct 
(Xiaochun Yu, University of Michigan) or Flag-tagged CHFR using FuGENE 6 (Roche).  
Lysates were harvested 24 hours later.  Cells were treated with 15 μM of MG132 
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(Calbiochem) for 10 hours and/or 200 ng/ml of nocodazole (Sigma-Aldrich) for 18 hours.  
To induce DNA damage, cells were treated with 0.3 μM aphidicolin for 24 hours.     
 
Spectral Karyotyping (SKY) and Metaphase Spreads 
MCF10A cells were treated with 50 ng/ml colcemid (Invitrogen) for 16h then 
collected and re-suspended in a hypotonic solution of 2.0% KCl and 2.0% Na3C6H5O7 for 
7 minutes at 37°C.  Metaphase spreads were then prepared and stained with Giemsa as 
previously described [20].  More than 25 metaphases were counted in triplicate.  
SKY analysis was performed according to the manufacturer's protocol (Applied 
Spectral Imaging) and as previously described [103].  Briefly, cells and slides were 
prepared as described above and unstained slides were aged in 2x SSC, treated with 
pepsin (Amreso; 30.0 µg/ml in 0.01 N HCl), then rinsed with PBS.  Slides were post-
fixed in 1.0% paraformaldehyde in PBS/MgCl2 and dehydrated in an ethanol series 
before and after denaturation in a 70% Formamide/2x SSC solution.  The denatured SKY 
probes (Vial 1, SKY kit, Vista, CA) were hybridized to the slides and incubated at 37°C 
for two days.  Following washings, antibodies (from vial 3 and 4, SKY kit) were added 
and incubated at 37°C for 1 hour each.  The slides were counterstained with DAPI in 
anti-fade solution.  All images were acquired using an SD200 SpectraCube spectral 
imaging system (ASI) attached to a Nikon E800 microscope consisting of an optical head 
(a Sagnac interferometer) coupled to a multi-line charge-coupled device camera 
(Hamamatsu, Bridgewater, NJ).  Spectral Imaging (v. 2.6.1) and Sky View (v. 1.6.2) 
were used to acquire and analyze the images, respectively.  The average of 10 metaphases 





Whole cell lysates were collected from approximately 80% confluent cultures.  
For samples analyzed for ubiquitination, 2 mM of N-ethylmaleimide (NEM; Sigma) was 
added to the lysis buffer.  Western blots were prepared as previously described [20].  
Membranes were blocked for one hour at room temperature, and incubated overnight at 
4°C in primary antibody.  The following antibodies were used: a mouse CHFR 
monoclonal antibody (1:500 dilution, Abnova Corp.), a custom rabbit polyclonal 
antibody to the N-terminus of CHFR (1:1000), and a rabbit anti-Aurora A antibody (1.0 
mg/ml, Xiaochun Yu).  Mouse anti-α-tubulin, anti-γ-tubulin, anti-acetylated α-tubulin, 
and rabbit anti-Flag (all Sigma-Aldrich), anti-α-tubulin (Cell Signaling Technology), and 
anti-GST (Santa Cruz) antibodies were all used at a 1:1000 dilution.  Anti-ubiquitin 
(1:100, Sigma) was also used and an anti-glyceraldehyde-3-phosphate dehydrogenase 
antibody (1:10,000, Abcam) was used for a loading control.  Blots were incubated in 
secondary antibody, anti-mouse:HRP or anti-rabbit:HRP, diluted in the blocking solution.  
We used the SuperSignal West Pico chemiluminescent kit (Pierce) and exposed the blots 
to Kodak Biomax XAR film.  Blots were stripped prior to re-probing.  Where applicable, 
blots were analyzed from three experiments to verify expression changes.  Densitometry 
was performed using the FluorChem 8900 imaging system (Alpha Innotech Corp.). 
 
GST pull-down 
A GST-CHFR fusion construct was created using the pGEX2T vector 
(Amersham) and expressed in the DH5α strain of E. coli.  Logarithmic E. coli cultures 
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were collected in lysis buffer (2.5 mM PMSF in 1.0% Triton X-100 with a protease 
inhibitor cocktail from Roche), sonicated, and then cleared by centrifugation.  One 
milligram of E. coli lysates was combined with 50.0 μl of washed Glutathione Sepharose 
4B beads (Amersham) for 2 hours at 4°C.  Then, 1.0 mg of whole cell lysates from 
MCF10A cells were added to the beads and incubated overnight at 4°C.  Following 
washes with NTEN200 buffer (20.0 mM Tris-HCl, 1.0 mM EDTA, 0.5% NP-40, 25.0 
μg/ml PMSF and 200.0 mM NaCl), bound proteins were eluted in 10.0 mM glutathione 
and collected by centrifugation.  Isolated proteins were identified by Western blotting.    
 
Immunoprecipitation 
Immunoprecipitations were completed according to manufacturer’s instructions 
using the Protein G immunoprecipitation kit (Sigma-Aldrich).  Briefly, whole cell lysates 
were combined with 10.0 μl of the specified antibody (mouse IgG1 isotype control from 
BD BioSciences, mouse anti-α-tubulin, or mouse anti-Flag M2 antibody) and diluted in 
the supplied 1x IP buffer and incubated for at least 2 hours at 4°C.  Then, 50.0 μl of 
protein G beads were added to the lysate/antibody mix overnight at 4°C.  Following 
washes, the immunoprecipitated lysates were boiled in the columns in 40.0 μl of 5x 
Laemmli’s loading buffer then eluted by centrifugation and analyzed by Western blotting. 
 
Immunofluorescence 
MCF10A cells were plated in two-chambered slides then fixed in 4.0% 
paraformaldehyde and blocked in 5.0% milk, 1.0% BSA in 0.025% TBS-Triton X100.  
Staining was performed using an anti-α-tubulin antibody (1:100, Sigma-Aldrich), a rabbit 
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anti-Aurora A antibody (1:50, Cell Signaling Technology) or an anti-histone H3-
phospho-Ser28 antibody (1:100, Upstate), which were hybridized in blocking buffer 
overnight at 4°C.  Slides were hybridized with an anti-mouse:Alexafluor594 or an anti-
rabbit:Alexafluor488 secondary antibody (Invitrogen) diluted to 1:200 in blocking buffer.  
Samples were preserved with ProLong Gold antifade reagent with DAPI (Invitrogen).  
 For BUBR1 and MAD2 localization, cells were prepared as above then 
permeabilized for 5 minutes in 0.5% TritonX-100 in 1x PBS after fixation.  Samples were 
blocked in 5.0% milk in 0.1% TBST then hybridized with an anti-BUBR1 antibody 
(Sigma) or an anti-MAD2 antibody (BD BioSciences) at a 1:200 dilution in blocking 
buffer overnight at 4ºC.  Slides were hybridized with an anti-mouse:Alexafluor594 
secondary antibody (1:500, Invitrogen) in blocking buffer for 1 hour at room temperature 
then preserved with ProLong Gold Anti-fade reagent with DAPI (Invitrogen).   
 
Microscopy 
We used a Leica DMRB miscroscope (W. Nuhsbaum, Inc.) with an external Leica 
EL6000 light source and a 63x or a 100x objective lens.  Images were recorded using a  
Retiga 2000R 12-bit digital camera and QCapture Pro v5.1 software (QImaging).   
 
Data Analysis 
Images were processed for resolution, magnification, and gamma settings using 
Adobe Photoshop CS2.  We used the ANOVA test for statistical significance and p<0.05 
was considered significant.  Error bars depict the standard error from triplicate 




Transient Loss of CHFR Expression Leads to Increased Aneuploidy 
We previously reported that the stable loss of CHFR expression by shRNA in 
IHMECs led to increased aneuploidy after prolonged culture in the genomically stable, 
but hyper-diploid MCF10A cell line [20].  Spectral karyotyping (SKY) of these cells 
indicated two distinct cell populations - minimally greater aneuploid or near tetraploid 
(Figure 4.1).  The parental karyotype of MCF10A cells, determined from eight metaphase 
spreads, was: 48,XX,1qhph,+del(1)(p?),t(3;9)(p14;p21),+del(7)(q?),i(8)(q10),t(3;5)(p?;?).  
The consensus karyotype of five metaphase cells from the minimally greater aneuploid 
population of MCF10A cells expressing CHFR shRNA  was:  
47~50,XX,+X,t(1;2)(q?;q?),t(3;9)(p14;p21),der(6)t(6;19)(p?;?),+del(7)(q?),t(3;5)(p?;?), 
der(11)t(8;11)(?;p?), t(15;18)(?;p?),+20.  The consensus karyotype from five metaphase 
cells for the near tetraploid population was 81~95,XXXX,-
1,t(1;2)(q?;q?),der(2)t(1;2)(q?;q?),-3,t(3;9)(p14;p21)x2,5,der(6)t(6;19)(p?;?)x2, 
+del(7)(q?),-9,t(3;5)(p?;?),-10,der(11)t(8;11)(?;p?)x2,-13,der(15)t(15;18)(?;p?)x2,-17,-
18x2,+20x2,-22.  In summary, MCF10A cells lacking CHFR gained chromosomes 20 
and three metaphase cells indicated a gain of chromosome X.  There were also four novel 
translocations t(1;2), t(6;19), t(8;11), and t(15;18) (Figure 4.1 B and C), suggesting that 
CHFR may regulate genomic stability via multiple mechanisms.  The finding that novel 
translocations were present in the CHFR knockdown cells compared to the parental cell 
line indicates the absence of clonal selection of cells from the parental line.  As an 
estimate of the frequency of tetraploidy, the incidence of bi-nucleated cells in the 




Figure 4.1: Stably decreased CHFR expression causes increased aneuploidy. 
(A) SKY analysis of parental MCF10A cells shows the characteristic karyotype of this 
genomically stable hyper-diploid cell line.  The karyotype of parental MCF10A cells 
was: 48,XX,1qhph,+del(1)(p?),t(3;9)(p14;p21),+del(7)(q?),i(8)(q10),t(3;5)(p?;?).  (B and 
C)  SKY analysis of MCF10A cells stably expressing shRNA against CHFR are either 
minimally more aneuploid (B) or nearly tetraploid (C) with novel chromosome 
translocations.  The consensus karyotype for the minimally aneuploid population was 
47~50,XX,+X,t(1;2)(q?;q?),t(3;9)(p14;p21),der(6)t(6;19)(p?;?),+del(7)(q?),t(3;5)(p?;?), 
der(11)t(8;11)(?;p?), t(15;18)(?;p?),+20.  The consensus karyotype for the near tetraploid 

















Figure 4.2:  The stable decrease of CHFR expression by shRNA results in increased 
incidence of bi-nucleated cells. 
 
A graphical representation of the frequency of bi-nucleated cells in parental MCF10A 
cells, those transduced with the scrambled shRNA control, and cells transduced to 
express stably shRNA against CHFR.  Nearly 12.5% of CHFR shRNA cells were bi-






CHFR shRNA cells compared to negative controls.  However, additional cells may have 
been tetraploid but contained within one nucleus, which was not assessed in this assay. 
To determine if the genomic instability arose due to prolonged culture following 
CHFR knockdown or clonal selection, MCF10A cells were transiently transfected with 
siRNAs targeting CHFR (“MCF10A:CHFR-siRNA cells”) and analyzed for increased 
aneuploidy and chromosome breakage within three days post transfection.  CHFR 
expression was decreased by at least 80% as detected by Western blotting at the 72 hours 
timepoint (Figure 4.3).  We observed no chromosome breaks on metaphase spreads 
following treatment with aphidicolin to induce DNA damage (Figure 4.4 and data not 
shown).  Of note, 32% of MCF10A:CHFR-siRNA cells were more aneuploid, typically 
having 49-59 chromosomes, compared to the mock transfected and non-targeting 
(“siControl”) negative control counterparts 72 hours after transient transfection (Figure 
4.5A and 4.5B, p≤0.001).  This indicated that increased aneuploidy occurs within a few 
days after CHFR expression is decreased and that it is not simply a result of prolonged 
cell culture conditions.  Given this, we wanted to elucidate the mechanism(s) by which 
amplified aneuploidy occurred in IHMECs that had lost CHFR expression. 
CHFR Regulates Chromosome Attachment to the Mitotic Spindle 
We performed immunofluorescence to visualize chromosomes during mitosis to 
examine the potential origins of increased aneuploidy in MCF10A:CHFR-siRNA cells.  
Nearly 25% of MCF10A:CHFR-siRNA cells had misaligned metaphase chromosomes 
when compared to the control cells (Figure 4.6A and 4.6B), and lagging chromosomes 
and chromosome bridges during anaphase (Figure 4.7).  Together, these results suggested 









Figure 4.3: A pool of four siRNAs substantially decreases CHFR expression. 
Western blotting shows >80% decrease in CHFR expression in MCF10A cells transiently 
transfected with siRNA against CHFR (“CHFR siRNA”) compared to untransfected 















            Mock                                  siControl                   CHFR siRNA 
 
 
Figure 4.4:  A transient decrease in CHFR expression by siRNA in MCF10A cells 
does not increase the incidence of chromosome breaks following treatment with 0.3 
μM aphidicolin.    
 
Untransfected (“Mock”) MCF10A cells, non-targeting siRNA-transfected cells 
(“siControl”), and cells transfected with a pool of siRNAs against CHFR were treated 
with 0.3 μM aphidicolin for 24 hours and exposed to 50 ng/ml colcemid for 21 hours to 
enrich for metaphase cells.  Metaphase spreads were created on glass slides and stained in 
Giemsa solution then visualized on a Leica DMRB microscope with a 100x objective 
lens to look for chromosome breaks.  Chromosome breaks were not observed for any of 
the three samples. 
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Figure 4.5: A transient loss of CHFR expression by siRNA in MCF10A cells results 
in increased aneuploidy within 72 hours.  
(A) Metaphase spreads show that MCF10A cells transfected with siRNA against CHFR 
(right panel) are more aneuploid when compared to the mock transfected and non-
targeting siControl negative control cells.  Bar = 25 μm.  (B) The graph shows the 
frequency of cells with increased aneuploidy in transiently transfected MCF10A cells.  










Figure 4.6: Lowered CHFR expression by siRNA causes misaligned chromosomes at 
the metaphase plate in MCF10A cells. 
 
(A) Sister chromatids did not properly migrate to the metaphase plate in MCF10A:CHFR 
siRNA cells (arrow, right panel).  Immunofluorescence (IF) detected phosphorylated 
histone H3-Ser28 (green) to identify metaphase chromosomes.  (B) A graph of the data 
shown in (A); 24% of cells with CHFR siRNA have chromosomes improperly located 
















Figure 4.7:  Targeting CHFR expression by siRNA causes lagging chromosomes 
during anaphase. 
Immunofluorescence indicated that MCF10A:CHFR-siRNA cells have lagging 
chromosomes and chromosome bridges during anaphase (arrow, right panels).  However, 
the negative control cells had a clear division between the two sets of separated sister 
chromatids that will be equally divided between the two daughter cells.  DNA was 
stained blue with DAPI.  White bar = 5 μm. 
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            To test this hypothesis, we studied the localization of two critical spindle 
checkpoint proteins, BUBR1 and MAD2, during mitosis.  Normally, both proteins have a 
punctate staining pattern early in mitosis, reflecting their localization to kinetochores 
prior to chromosome segregation at anaphase.  Staining becomes diffuse later in mitosis 
after all chromosomes are attached to the mitotic spindle.  Normal BUBR1 and MAD2L1 
staining patterns were observed in negative control cells (Figure 4.8).  In contrast, 
MCF10A:CHFR-siRNA cells demonstrated diffuse BUBR1 and MAD2 staining early in 
metaphase (Figure 4.8A and 4.8B, right panels).  Although Western blotting showed that 
CHFR siRNA did not change MAD2 or BUBR1 expression, immunoprecipitation 
experiments revealed that CHFR could interact with MAD2, but not BUBR1 (Fig. 4.9, 
data not shown) 
As noted above, some cells with stably decreased CHFR by shRNA were 
tetraploid (Figure 4.1).  In fact, 6% of transiently transfected MCF10A:CHFR-siRNA 
cells were binucleated, suggesting tetraploidy, compared to only about 1% of negative 
control cells (Fig 4.10A and 4.10B, p<0.05).  This was confirmed by the occasional 
tetraploid MCF10A:CHFR-siRNA metaphase spread when cells were assessed for 
changes in aneuploidy frequency.   
CHFR Modulates Expression of Aurora A 
The chromosome mis-segregation phenotypes in MCF10A:CHFR-siRNA cells 
were highly reminiscent of mouse embryonic fibroblasts (MEFs) that over-express 
Aurora A [99].  Previous studies also performed in MEFs from CHFR knockout mice 
showed similar mitotic defects and Aurora A over-expression [8].  To assess if Aurora A 
expression or localization was altered in our model, we performed Western blotting and  
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Figure 4.8: The mitotic spindle checkpoint proteins BUBR1 and MAD2 are 
mislocalized during metaphase following the loss of CHFR expression by siRNA. 
Immunofluorescence to visualize BUBR1 and MAD2 revealed that cells with CHFR 
siRNA (right panels) had a diffuse BUBRI and MAD2 staining pattern (red, A and B 
respectively), indicating mislocalization.  Control cells had the characteristic punctate 
staining patterns for BUBR1 and MAD2.  DNA was stained blue with DAPI.   









                
 
Figure 4.9: A Flag-tagged CHFR construct can interact with the mitotic spindle 
checkpoint protein MAD2, but not BUBR1. 
 
(A) Endogenous MAD2 interacts with CHFR.  HEK293 cells were transfected with a 
Flag-tagged CHFR construct, with or without nocodozaole treatment.  
Immunoprecipitation (IP) with an anti-Flag antibody was performed to isolate CHFR and 
subsequently analyzed by Western blotting (WB) for the Flag:CHFR fusion protein and 
endogenous MAD2.  “Input” indicates 5% of the lysates used for the IP reaction.  (B) The 
experiment was performed as above, but Western blotting was used to detect endogenous 




Figure 4.10: Decreased CHFR expression by siRNA causes an increase in the 
incidence of bi-nucleated giant cells.  
 
(A) Immunofluorescence to detect cytoskeletal α-tubulin (red) during interphase shows 
that MCF10A:CHFR-siRNA cells become binucleated (subpanels i and l; arrow) 
compared to the negative control cells (subpanels c and f).  DNA was stained blue with 
DAPI.  White bar = 50 μm. (B) Quantification of the data shown in (A) in which 6% of 
cells lacking CHFR became bi-nucleated as opposed to about 1% incidence in control 
cells.  One asterisk (*): p<0.05.  
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found that MCF10A:CHFR-siRNA cells had much greater Aurora A expression 
compared to the control cells (Figure 4.11A).  It has been demonstrated that CHFR can 
interact with, and ubiquitinate, Aurora A by immunoprecipitation in vitro in non-
mammary human cell lines [8].  We also found that Flag-tagged Aurora A could interact 
with endogenous CHFR in MCF10A cells by IP (Figure 4.11B).  The physical interaction 
of these two proteins, combined with Aurora A over-expression in MCF10A:CHFR-
siRNA cells, substantiates initial observations that Aurora A is a target for CHFR-
mediated ubiquitination for degradation. 
Early in mitosis, Aurora A localizes to centrosomes where it is involved in their 
maturation and separation and spindle formation [104].  We found that Aurora A 
localized strongly to the centrosomes during metaphase in control cells, as evidenced by 
the two distinct dots that colocalized to the spindle poles, as expected.  However, in 16% 
of MCF10A:CHFR-siRNA cells, more than two Aurora A foci were detected, indicating 
increased Aurora A expression and  centrosome amplification (Figure 4.12 p<0.05). 
CHFR Regulates α-tubulin Expression 
In MCF10A:CHFR-siRNA cells, the spindle was more condensed with poor polar 
microtubule formation (Figure 4.12A, bottom panel).  It was hypothesized that CHFR 
may interact with tubulin proteins.  A GST pull-down using a GST:CHFR fusion protein 
and lysates from MCF10A cells was performed.  CHFR was found to interact with α-
tubulin, but not β- or γ-tubulin when the MCF10A cells were treated with nocodazole 
(Figure 4.13 and data not shown).  This was confirmed by immunoprecipitation, though 









Figure 4.11:  Endogenous CHFR interacts with Aurora A kinase and regulates its 
expression in MCF10A cells. 
(A) MCF10A:CHFR-siRNA cells over-express Aurora A, as shown by Western blotting, 
compared to control cells.  GAPDH was used as a loading control.  (B) Flag:Aurora A 
interacts with endogenous CHFR by co-IP.  Lysates from MCF10A cells transiently 
transfected with Flag-tagged Aurora A were subjected to IP with an anti-Flag (M2) 
antibody then probed for CHFR or Flag by Western blotting (WB) using rabbit 






         
 
 
Figure 4.12:  Lowered CHFR expression in MCF10A cells leads to increased 
numbers of Aurora A foci, suggesting centrosome amplification. 
 
(A) Immunofluorescence for Aurora A (green) indicates that MCF10:CHFR-siRNA cells 
(bottom row) have greater than two Aurora A foci when compared to two foci in negative 
control cells during metaphase.  Cells were stained with DAPI (blue) for DNA and for α-
tubulin (red) to see the spindle.  Note the compacted, disorganized mitotic spindle (red) in 
CHFR-siRNA cells (subpanel l versus subpanels d and h).  (B) Quantification of the data 
in (A), in which 16% of cells without CHFR have greater than two Aurora A foci.  One 







Figure 4.13: CHFR interacts with α-tubulin by GST pull-down and 
immunoprecipitation. 
 
(A) A GST pull-down using a GST:CHFR fusion protein shows that CHFR can interact 
with α-tubulin, but not β- or γ-tubulin from MCF10A whole cell lysates as shown by 
Western blotting for tubulins.  The “input” is 10% of the MCF10A whole cell lysates 
used for the GST pull-down.  MCF10A cells were either untreated (-Noc) or treated with 
nocodazole (+Noc) prior to lysate collection.  (B) CHFR interacts with α tubulin by IP.  
A Flag:CHFR construct was transfected into HEK293 cells and the lysates were used for 
IP with either anti-Flag or anti-α tubulin mouse antibodies then Western blotted (WB) 
with either anti-Flag or anti-α tubulin rabbit antibodies.  Cells were either untreated or 








To determine if CHFR ubiquitinates α-tubulin, MCF10A cells transfected with 
control or CHFR siRNAs were treated with the proteasome inhibitor MG132 with or 
without nocodazole.  Immunoprecipitation for α-tubulin then immunoblotting for 
ubiquitin indicated that CHFR can ubiquitinate α-tubulin during nocodazole exposure, as 
evidenced by the loss of ubiquitin signal in MCF10A:CHFR-siRNA cells (Figure 4.14, 
lane 3 vs. lane 6).  Western blotting confirmed that CHFR can regulate α-tubulin as there 
was a reproducible increase in α-tubulin protein levels, but not in β-or γ-tubulin, in 
MCF10A:CHFR-siRNA cells (Figure 4.15 and data not shown, p<0.05).  The amount of 
acetylated α-tubulin in MCF10A:CHFR-siRNA cells also was consistently double that of 
controls (Figure 4.15 p<0.05).  
Discussion 
The work presented here indicates that CHFR is important for the maintenance of 
genomic stability in mammary epithelial cells.  Our results support and help explain the 
findings of aneuploidy in MEFs from Chfr-/- mice.  The observed chromosome 
rearrangements that we noted by spectral karyotyping likely resulted from prolonged 
culture and the disruption of DNA damage response genes secondary to the increase in 
aneuploidy, which we have shown can develop within a few days after CHFR expression 
is decreased.  To the contrary, the more frequent presence of additional chromosomes 
with a numeric change in chromosome number, or aneuploidy, in siRNA-treated cells 
provide powerful evidence that CHFR is required for genomic stability via proper 
chromosome segregation during mitosis.  Furthermore, the lack of chromosome breaks in 
MCF10A cells transiently expressing siRNA against CHFR suggested that CHFR might 






Figure 4.14:  CHFR can ubiquitinate α-tubulin during nocodazole treatment. 
 
MCF10A cells were cultured in 15 μM MG132 for 10 hours and either untreated or 
simultaneously treated with 200 ng/ml nocodazole for 18 hours.  Western blotting of 
immunoprecipitated α-tubulin for ubiquitin shows that the amount of ubiquitinated α-
tubulin is dramatically decreased in MCF10A:CHFR-siRNA cells treated with 














Figure 4.15: CHFR regulates α-tubulin expression and the amount of acetylated α-
tubulin. 
 
(A) Western blotting reveals that MCF10A:CHFR-siRNA cells have a modest increase in 
unmodified and acetylated α-tubulin protein levels compared to control cells.  The box 
encompasses the normalized expression of each of the proteins, as determined by 
densitometry.  (B)  Quantification of the data presented in (A) from triplicate 
experiments, showing a reproducible 2-fold increase in acetylated α-tubulin protein 
levels and a modest increase in total α-tubulin expression.  (*) denotes p<0.05. 
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aphidicolin.  This conclusion is supported by previous studies in which CHFR expression 
did not alter the DNA damage response following treatment with other genotoxic 
reagents [7, 17]. 
The mis-localization of the key checkpoint proteins, BUBR1 and MAD2, 
following CHFR knockdown indicated an impaired spindle checkpoint, which would 
help to explain the observed increase in aneuploidy.  With an impaired spindle 
checkpoint, cells with decreased CHFR expression could enter anaphase without all of 
their chromosomes localized to the metaphase plate, leading to the appearance of lagging 
chromosomes and unequal chromosome segregation amongst the two daughter cells.  
One potential outcome of improper chromosome segregation is that the cell can bypass 
cytokinesis, resulting in bi-nucleated cells and tetraploidy, which was also observed in 
this work [105].  Of interest, our work strongly agrees with previous findings that the 
yeast orthologs of CHFR, Dma1 and Dma2, also function in regulating the spindle 
checkpoint and cytokinesis [11, 12].   
It is quite interesting to note that CHFR can interact with one spindle checkpoint 
protein, MAD2, but not another, BUBR1.  This suggests that CHFR interacts with MAD2 
when it is not in the spindle checkpoint complex at the kinetochore.  Despite CHFR’s E3 
ubiquitin ligase activity, MAD2 (and BUBR1) expression was not altered in CHFR 
knockdown cells, indicating that the protein-protein interaction between CHFR and 
MAD2 is not for the purposes of regulating MAD2 protein levels.  However, it has been 
shown that CHFR has the potential to regulate lysine-63 based ubiquitin chains on target 
proteins, which would likely alter the target protein’s activity or function rather than 
target it for degradation by the proteasome [5].  Further work is suggested in order to 
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determine if CHFR can create Lys63-based ubiquitin chains or can mono-ubiquitinate 
MAD2 to alter its localization and/or function.  Additional studies to determine if CHFR 
can interact with, or regulate, other mitotic spindle checkpoint proteins, such as Cdc20 or 
MAD1, will also be required to understand further the role of CHFR in the mitotic 
spindle checkpoint.  It will also be interesting to find out if CHFR interacts with the open 
or closed conformation of MAD2, or both.  Supporting our hypothesis that CHFR may 
participate in the spindle assembly checkpoint, recently published bioinformatics 
evidence indicated that CHFR might contain a KEN box motif.  This indicates that CHFR 
may be targeted for proteasome-mediated degradation by the anaphase-promoting APC/C 
complex, which is a critical component of the mitotic spindle assembly checkpoint and 
the regulatory complex that controls mitotic exit [26].  A model of the mitotic spindle 
checkpoint, and where CHFR may participate, is shown in Figure 4.16.    
We were able to confirm the previously published finding that CHFR can regulate 
Aurora A expression.  Aurora A is amplified and over-expressed in many cancers, 
including breast, and over-expression in cultured cells leads to transformation [102, 104].  
In addition, a transgenic mouse over-expressing Aurora A in the mammary epithelium 
leads to tumor formation and genomic instability [106].  CHFR was recently 
characterized as having tumor suppressor functions and, as shown here, many of its 
genomic instability phenotypes resemble Aurora A over-expression; therefore, we 
propose that one major mechanism by which CHFR inhibits oncogenesis may be through 
its negative regulation of Aurora A [8, 20].  Of interest, novel drugs are being generated 
that target the Aurora kinases [107].  Since decreased CHFR expression has been linked 





Figure 4.16:  How CHFR may participate in the mitotic spindle assembly 
checkpoint to regulate MAD2 and BUBR1 localization. 
 
The cytosolic open conformation of MAD2 is bound to Cdc20 until it is recruited to an 
unattached kinetochore in order to interact with MAD1.  CHFR may interact with MAD2 
here and be required for its localization to the kinetochore.  BUBR1 is also bound to 
Cdc20, in addition to BUB3 and CENP-E at the kinetochore.  CHFR may be indirectly or 
directly required for BUBR1 localization here at the kinetochore.  MAD2, BUBR1, 
BUB3 and Cdc20 bind the anaphase-promoting complex (APC) to inhibit it from 
initiating anaphase.  When the kinetochore becomes attached to a microtubule of the 
mitotic spindle, BUBR1, BUB3, and MAD2 are released from the kinetochore and detach 
from APC to activate it and allow the initiation of anaphase and the cleavage of separase.  







when taxanes and Aurora kinase inhibitors are both used for treatment. 
These findings also indicate that CHFR may play a role in regulating α-tubulin 
turnover or stability, especially following microtubule stress.  This is the first clue as to 
how the “CHFR checkpoint” responds to microtubule poisons, though an unidentified 
signaling cascade also is likely to be involved in this checkpoint.  The ubiquitination and 
possible degradation of α-tubulin may be necessary to remove those α/β tubulin dimers 
that are targeted by microtubule poisons.  In unstressed cells, CHFR may also be required 
for proper spindle formation, as indicated in Figure 4.12A.  Aurora A kinase is also 
required for proper spindle formation, supposedly through its positive regulation of a 
protein called hepatoma up-regulated protein (HURP) [109].  HURP is required for both 
chromosome congression and alignment and for the polymerization and stabilization of 
microtubules during mitotic spindle formation.  It will be interesting to determine in the 
future if CHFR’s ability to control spindle formation is via its upstream regulation of 
Aurora A.   
We also noted that one of the effects of decreasing CHFR expression is the up-
regulation of the amount of acetylated α-tubulin protein.  One of the characteristics of 
stabilized microtubules is the acetylation of α-tubulin on residue lysine 40.  Acetylated 
α-tubulin is associated with decreased microtubule turnover and is localized to the 
mitotic spindle, centrosomes, and the mitotic midbody [110, 111].  An increase in 
acetylated α-tubulin, such as that observed here, would likely result in over-stabilized 
microtubules, which would hinder mitotic spindle movement or would prevent its proper 
formation.  This may help to explain why CHFR negative cells are more sensitive to 
taxanes.  The cellular stress of the over-stabilized acetylated microtubules, combined 
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with stress induced by microtubule poisons, may enable the cell to surpass a threshold of 
tolerable stress that would result in apoptosis.  This hypothesis is supported by reports of 
a synergistic effect on both apoptotic response and microtubule stabilization, as indicated 
by acetylated α-tubulin, when endometrial cancer cells are treated with both the histone 
deacetylase inhibitor (HDI) trichostatin A and paclitaxel [112].  Interestingly, some of the 
targets of HDIs are also tubulin deacetylase proteins, such as HDAC6 and SIRT2 [113, 
114].  Recent studies also show that treating cells with HDIs down-regulates Aurora A 
expression [115].  Therefore, it will be interesting to determine in future studies if the 
synergistic effect between HDIs and taxanes is different in CHFR-positive versus CHFR-
negative cancer cells. 
The finding that CHFR knockdown results in increased amounts of acetylated α-
tubulin is particularly interesting because another protein found to initiate a “CHFR 
checkpoint-like” response is SIRT2, a tubulin and histone deacetylase [24].  SIRT2 over-
expression is a phenocopy of CHFR over-expression in regards to the regulation of 
mitotic entry and response to mitotic stress.  Therefore, hypothetically, decreased SIRT2 
expression should resemble decreased CHFR expression in both response to mitotic 
stress and the amount of acetylated α-tubulin in the cell.  Future studies should determine 
if the increase in acetylated α-tubulin after decreased CHFR expression is due to SIRT2 
or through the activation of Aurora A-regulated HURP. 
I have also found that CHFR over-expression is toxic to many breast cell lines 
independent of the method of transfection or retroviral transduction (both transient and 
stable; data not shown).  This suggests that CHFR expression must be tightly regulated – 
too much is toxic whereas too little causes genomic instability and tumorigenesis.  This is 
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reminiscent of other mitotic checkpoint proteins, such as MAD2, in that both too little 
and too much of the protein are deleterious [116].  In support of this finding, over-
expression of the yeast orthologs of CHFR in S. cerevisiae dramatically increase the 
cells’ doubling time due to delays in both the G1 and the G2/M phases of the cell cycle 
[28].  Future work on the mechanism of CHFR over-expression toxicity likely will 
answer many of the questions that remain about the function of CHFR.  However, I 
speculate that CHFR target proteins are not being properly modified or targeted for 
degradation when CHFR is over-expressed, resulting in either impaired cell cycle 
progression or an up-regulated apoptotic response.            
These findings have led me to suggest a model for how CHFR may regulate 
genomic instability and/or tumorigenesis (Figure 4.17).  We propose that decreased or 
lost CHFR expression causes over-expression of Aurora A and both unmodified and 
acetylated α-tubulin, and mis-localization of MAD2.  Aurora A over-expression could 
lead to centrosome amplification, an impaired spindle checkpoint, and possibly defective 
mitotic spindle formation, leading to aneuploidy and impaired cytokinesis.  The MAD2 
mis-localization also causes an impaired spindle checkpoint response.  The increase in 
acetylated α-tubulin could cause stress on the mitotic spindle.  Both pathways would lead 
to genomic instability, contributing to tumorigenesis.  As indicated by the generality of 
this model, much research remains in order to elucidate the role of CHFR in regulating 
mitosis and genomic instability.  Cancer often develops in concert with the loss of cell 







Figure 4.17: A proposed model of how CHFR regulates genomic instability, which 
could lead to tumorigenesis. 
 
Decreased or lost CHFR expression causes Aurora A, α-tubulin, and acetylated α-tubulin 
over-expression and MAD2 mis-localization.  The increase in acetylated α-tubulin occurs 
by an unknown mechanism, possibly through HURP or SIRT2 and may stress the mitotic 
spindle.  Aurora A over-expression causes centrosome amplification.  Both Aurora A 
over-expression and MAD2 mis-localization result in an impaired spindle checkpoint, 
contributing to aneuploidy and/or failed cytokinesis.  Both processes lead to mitotic 
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CHFR Has Tumor Suppressive Functions and Alters Cellular Response to 
Microtubule-Targeting Chemotherapeutic Drugs 
  CHFR was first characterized as a cell cycle checkpoint protein that delayed 
mitosis, in prophase, in response to microtubule-targeting drugs such as paclitaxel and 
nocodazole [3].  Following its initial discovery, subsequent work has shown that CHFR 
mRNA expression was low or lost in cancers compared to controls and that this loss, 
often due to promoter hyper-methylation, correlated with an increased sensitivity to 
microtubule-targeting drugs [40, 53].  These data suggested that CHFR might be a tumor 
suppressor that could function as a biomarker for chemotherapeutic response to taxane 
treatment. 
 To begin testing the hypothesis that CHFR may have tumor suppressive 
capabilities in breast cancer, the mRNA and protein expression levels of CHFR were 
analyzed.  It was determined that CHFR mRNA expression was low or lost in 18% of 
cultured breast cancers by quantitative RT-PCR; however, 41% of cultured breast cancer 
cell lines had low or lost CHFR protein expression.  This finding indicated a single 
method of analyzing CHFR mRNA levels did not predict protein expression, which is 
particularly important when trying to associate CHFR expression with clinical and 
pathological variables.  Some of the discrepancy between mRNA and protein expression, 
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particularly in the MCF10A, SKBr3, and MDA-MB-231 cell lines, suggested that CHFR 
expression might be regulated post-transcriptionally or post-translationally.  Some of the 
potential mechanisms of post-translational regulation include the ability of CHFR to 
auto-ubiquitinate, poly(ADP-ribosyl)ation, and phosphorylation [5, 7, 9, 16].  Of interest, 
immunohistochemistry from 142 primary invasive breast cancer patient samples revealed 
that 36% of the samples did not stain for CHFR expression, a relatively high frequency of 
occurrence.  The finding that more breast cancers had low or lost CHFR expression 
compared to the very infrequent occurrence of over-expression (about 5% of samples), 
hinted that CHFR may have tumor suppressive qualities.   
To mimic the loss of CHFR expression, two IHMEC lines, HPV4-12 and 
MCF10A, were engineered to lower CHFR expression by RNAi with a stably expressed 
short hairpin RNA (shRNA) or a transient transfected pool of short interfering RNAs 
(siRNAs).  The cells that had lost CHFR expression exhibited several phenotypic changes 
relevant for tumorigenesis.  These cells had a faster population growth rate, increased 
mitotic indices both with and without nocodazole exposure, enhanced invasiveness and 
motility, amplified colony formation in soft agar only for HPV4-12 cells, and an 
epithelial-to-mesenchymal transition in morphology for MCF10A cells.  Both cell lines 
also became more aneuploid after CHFR knockdown when compared to the hyper-
diploid state of the parental cell lines.  In complementary experiments, over-expressing 
CHFR in the low-expressing breast cancer cell line Hs578T caused the reversal of many 
tumorigenic phenotypes, making these cells more closely resemble non-tumorigenic 
immortalized cells or normal mammary epithelial cells.  In particular, CHFR over-
expressing cells had a slower growth rate, a decreased mitotic index with and without 
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nocodazole treatment, and a nearly abolished invasive potential and motile ability.  The 
dramatic results of altering CHFR expression in cultured breast cells support the 
hypothesis that CHFR has tumor suppressive functions in breast cancer. 
 One of the most striking findings from these experiments was the dramatic 
influence of CHFR expression on cellular invasion through Matrigel and motility.  This 
work is the first report of this association and is highly important, as it was not a 
predicted outcome of altering CHFR expression.  The ability for cells to move and invade 
the surrounding tissues and extracellular matrix is required for cancer metastasis.  
CHFR’s strong influence on invasion and motility in cell culture models warrants further 
testing in mouse models and from annotated primary breast cancer samples to determine 
if its expression can indicate the potential for tumor metastasis.  Of note, the epithelial-to-
mesenchymal transition in cellular morphology that was observed in MCF10A cells with 
decreased CHFR expression is also associated with increased invasive potential, likely 
due to altered cell-cell contacts and enhanced cell motility [117].  Additionally, since 
CHFR monitors microtubule stability and acetylation, it is possible that this ability to 
regulate the cytoskeleton would have an impact on cellular motility and invasion, both of 
which require a dynamic rearrangement of the cytoskeleton in order to occur.  In fact, 
previous reports have shown that acetylated alpha tubulin is present at the tail processes 
of motile fibroblasts [118].  The increase in acetylated alpha tubulin that results from loss 
of CHFR expression by RNAi likely contributes to the increased motility and invasion of 
these cells.   
 Another interesting result after the knockdown of CHFR expression were the 
cells’ increased apoptotic response to both nocodazole and paclitaxel exposure.  
126 
 
However, this change was only observed in MCF10A cells, not HPV4-12 cells.  A 
potential explanation for this difference is the method in which these two cells were 
immortalized.  MCF10A cells arose spontaneously and were later found to have been 
immortalized after a chromosome translocation t(3;9)(p14;p21) that disrupted the 
p15/p16 gene in addition to other chromosomal rearrangements [91, 92].  The HPV4-12 
cells were immortalized with the human papilloma virus E6 and E7 proteins, which 
impair the critical p53 and pRb tumor suppressor proteins [91].  This suggested that 
perhaps the p53 or pRb tumor suppressors might be critical for the apoptotic response to 
taxanes in CHFR-null cells.  Though the altered apoptotic response to taxanes provided 
further evidence that CHFR may be a biomarker for chemotherapeutic response, this was 
the first report to indicate that other genetic and molecular factors might also need to be 
considered in addition to CHFR expression. 
 Finally, immunohistochemistry for CHFR expression on an annotated breast 
cancer microarray found that positive CHFR expression correlated with a small (less than 
2 cm) tumor size.  This supported the finding in cell culture models that over-expression 
of CHFR expression decreased growth rates, which could be thought of as creating a 
smaller tumor in vivo.  Of interest, a small tumor size is one of the criteria used to label a 
cancer as an early stage tumor.  In addition, there was a trend of positive CHFR 
expression being associated with estrogen receptor positive breast cancers.  This is 
particularly relevant given previous clinical trials have shown that ER-positive, and 
therefore possibly CHFR-positive, breast cancers did not respond as well to paclitaxel 
treatment as ER-negative breast cancers [78-80].  This corresponds well with the fact that 
CHFR-positive cells are more resistant to apoptosis following taxane exposure when 
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compared to their CHFR-negative counterparts.  This trend between CHFR and ER status 
might also be a clue to identifying the molecular pathway through which CHFR regulates 
cellular proliferation.  Taken together, the results from altering CHFR expression in 
cultured mammary epithelial cells and the findings in primary invasive breast cancers 
indicate that CHFR has potent tumor suppressive qualities. 
CHFR Contributes to the Maintenance of Genomic Stability 
 Both the work presented here and previous studies using mouse embryonic 
fibroblasts from Chfr knockout mice described the occurrence of aneuploidy after 
prolonged loss or decreased CHFR expression [8].  To determine the mechanism of 
increased aneuploidy, CHFR expression was transiently decreased by siRNAs and 
chromosome segregation was analyzed using immunofluorescence.  MCF10A cells 
treated with siRNA against CHFR became more aneuploid within 72 hours and four key 
mitotic defects were observed that could explain the origins of the increased aneuploidy: 
(1) misaligned chromosomes at the metaphase plate, (2) lagging chromosomes during 
anaphase, (3) multi-polar mitotic spindles, and (4) multi-nucleated giant cells.  Aside 
from the poorly formed multi-polar mitotic spindles, the other mitotic defects indicated 
an impaired mitotic spindle assembly checkpoint.  Therefore, the localization of the key 
spindle checkpoint proteins MAD2 and BUBR1 were analyzed.  Indeed, both MAD2 and 
BUBR1 were not properly localized to the kinetochores in MCF10A cells with decreased 
CHFR expression by siRNA; rather, they were diffusely distributed throughout the 
cytoplasm indicating an impaired spindle checkpoint.   
 This is the first report that CHFR may participate in a checkpoint other than the 
initially described prophase checkpoint that responds to microtubule stress.  Though the 
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results are preliminary, the fact that CHFR may help to regulate the spindle assembly 
checkpoint is an exciting new finding.  However, there is debate that these two 
checkpoints may actually be the same checkpoint, as earlier studies have shown that the 
spindle checkpoint also delays mitosis in response to microtubule stress [119, 120].  It is 
apparent that further work is required to determine if the CHFR-mediated prophase 
checkpoint is independent of the spindle assembly checkpoint and how CHFR functions 
in the checkpoint(s).  I hypothesize that the two checkpoints are intimately linked for the 
proper regulation of mitotic events and that CHFR plays a major role in controlling both 
checkpoints, either directly or as an upstream regulator of signaling proteins and their 
degradation.        
Novel CHFR Interacting Proteins 
 Three proteins required for proper chromosome segregation were identified that 
could interact with CHFR: MAD2, Aurora A kinase, and α-tubulin.  The preliminary data 
indicating an interaction between CHFR and MAD2 is a novel finding that links CHFR 
with the spindle checkpoint.  Although CHFR can interact with MAD2, there was no 
evidence that CHFR can regulate the amount of MAD2 protein, as the amount of MAD2 
does not change when CHFR expression is altered.  Therefore, CHFR likely does not 
control the degradation of MAD2, but may change its function, localization, or 
conformation via lysine-63 polyubiquitin chains or by mono-ubiquitination.  
Previously published work indicated that CHFR could interact with, and 
ubiquitinate, Aurora A kinase in order to regulate its expression [8].  This protein 
interaction was confirmed in this work in MCF10A mammary epithelial cells and it was 
noted that decreased CHFR expression resulted in Aurora A over-expression, presumably 
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due to a lack of CHFR-mediated degradation.  This interaction has many implications as 
Aurora A kinase is an important regulator of many mitotic processes including 
centrosome duplication and maturation, mitotic spindle formation, and spindle 
checkpoint function [96-98].  Therefore, CHFR may be a key mitotic checkpoint protein, 
as it appears to be upstream of proteins such as Aurora A and PLK-1 kinases that are 
crucial to the regulation and progression of mitotic events.   
 Finally, this work identified a novel interaction between CHFR and α-tubulin by 
both GST pull-down and immunoprecipitation experiments.  Of interest, CHFR was 
found to ubiquitinate α-tubulin when cells were treated with nocodazole, which was the 
first clue as to how CHFR is involved in the cellular response to microtubule stress.  In 
support of this, Western blotting indicated that there was a slight, but reproducible, 
increase of α-tubulin protein when CHFR expression was decreased by siRNA.  This 
would cause a change in the carefully regulated 1:1 stoichiometry of α- and β-tubulin 
dimers, which may alter the kinetics of microtubule assembly.  Finally, when CHFR 
expression was decreased there was also an increase in acetylated α-tubulin, which is a 
key component of the mitotic spindle.  This may be due to either the deregulation of the 
Aurora A-controlled protein HURP or the down-regulation of another potential protein in 
the CHFR checkpoint, the tubulin deacetylase SIRT2 [24, 98, 109, 113].  This increase in 
stabilized, acetylated α-tubulin would likely cause increased stress on the mitotic spindle 
and may impair proper spindle dynamics for chromosome segregation.   
In summary, CHFR appears to interact with several key mitotic proteins including 
Aurora A, MAD2, α-tubulin, and potentially PLK-1.  The number of prospective CHFR 
interacting proteins could be large, but CHFR may also have only a limited number of 
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interacting proteins.  Unfortunately, there is currently no information as to how CHFR 
recognizes its target proteins.  However, CHFR’s primary function seems to be regulating 
protein function and turnover via different methods of target protein ubiquitination (ie: 
Lys48 vs. Lys63 polyubiquitin chains) as a means to control cell cycle progression and 
checkpoints.  The protein interactions described above and those described in other 
reports, and their potential downstream effects, are summarized in Figure 5.1. 
Future Directions 
Stemming from the results presented here, I believe there are two major directions in 
which future work on CHFR should continue.  First, several aspects of the potential 
tumor suppressive functions of CHFR remain to be tested.  Several of the findings 
presented here could be pursued further, such as the mechanism(s) through which CHFR 
regulates cellular motility and invasion and how CHFR expression may be related to 
estrogen receptor (ER) expression and function.  In addition, cells with altered CHFR 
expression (i.e.: decreased expression by RNAi in IHMECs or over-expression in breast 
cancer cell lines) should be injected into immuno-compromised mice to determine if 
changes in CHFR expression lead to altered tumorigenicity.  Using additional 
information from breast cancer patients, CHFR expression should also be tested for 
correlation with other clinical and pathological variables such as tumor stage, the 
presence of distant (non-lymph node) metastasis, and patient response to chemotherapy 
treatment with taxanes.    
A second direction for future research on CHFR is to define further its function in 







Figure 5.1: CHFR may be an upstream regulator of many proteins involved in 
mitotic events in order to prevent cellular transformation and aneuploidy. 
 
There is evidence that CHFR can negatively regulate α-tubulin, Aurora A, PLK-1 in 
addition to interacting with MAD2 for unknown reasons.  These four potential target 
proteins control intracellular trafficking, cellular motility, and many aspects of mitotic 
progression and mitotic spindle assembly.  Cellular transformation and/or aneuploidy can 







warrants further experimentation to determine: (1) which domains of CHFR and MAD2 
interact, (2) if CHFR can ubiquitinate MAD2, (3) if there a direct interaction between the 
two proteins, or do they function in a complex, and (4) whether CHFR interacts with the 
open or closed conformation of MAD2.  Elucidating the subcellular localization of CHFR 
during the course of the cell cycle, particularly with live cell imaging, will also clarify 
how CHFR may function to regulate the cell cycle.  Further, complementation tests to 
determine if CHFR directly influences the mitotic spindle assembly checkpoint or if it 
regulates the checkpoint via its regulation of target proteins such as Aurora A are 
required.  Finally, finding the reason why the over-expression of CHFR can be toxic will 
greatly expand our knowledge of how CHFR functions to regulate the cell cycle and 
mediate the cellular response to microtubule stress.   
Since there is relatively little known about CHFR, there are numerous paths in 
which future research should be directed.  However, the work presented here has 
provided several new leads as to which directions will be fruitful in order to answer the 
many questions that remain regarding the functional role of CHFR in cell cycle 
regulation, genomic instability, and cancer. 
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